

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Discovery of potential immune epitopes and... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/9-999/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/9-999" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Discovery of potential immune epitopes and peptide vaccine design - a prophylactic strategy against Rift Valley fever virus" />
    
            <meta name="og:title" content="F1000Research Article: Discovery of potential immune epitopes and peptide vaccine design - a prophylactic strategy against Rift Valley fever&lt;i&gt; &lt;/i&gt;virus.">
            <meta name="og:description" content="Read the latest article version by Maruf Ahmed Bhuiyan, Syeda Tasnim Quayum, Foysal Ahammad, Rahat Alam, Abdus Samad, Zulkar Nain, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="27552">
            <meta name="article-id" content="24975">
            <meta name="dc.title" content="Discovery of potential immune epitopes and peptide vaccine design - a prophylactic strategy against Rift Valley fever&lt;i&gt; &lt;/i&gt;virus">
            <meta name="dc.description" content=" Background: Rift Valley fever virus (RVFV) is an emerging arbovirus infecting both animals and humans. Any form of direct contact with body fluids, blood or tissue of infected animals is the mode of transmission of this pathogen. Despite being an emerging virus, no proper vaccinations are yet available for the public. Our objective is to compose a multiepitope vaccine utilizing immuno-bioinformatics as a strategy against RVFV. 
 Methods: To identify immunodominant epitopes and design a potent vaccine candidate, we applied a series of immunoinformatic approaches with molecular dynamics and immune response simulation frameworks. 
 Results: A glycoprotein with the highest antigenicity was selected and employed for determining promising epitopes. We selected T cell epitopes based on their immunological potencies and cytokine inducing properties, while B cell epitopes were selected based on their antigenic features. Finally, we selected four cytotoxic T-lymphocyte, two helper T-lymphocyte, and three linear B-lymphocyte epitopes that were arranged into a vaccine construct with appropriate adjuvants and linkers. The chimera protein was modeled, refined, and validated prior to docking against toll-like receptor 4. Docking studies suggest strong binding interactions while dynamics simulation revealed the stable nature of the docked complex. Furthermore, the immune simulation showed robust and prolonged immune responses with rapid antigen clearance. Finally, codon optimization and cloning conducted with Escherichia coli K12 suggests high translation efficiency within the host system. 
 Conclusion: We believe that our designed multiepitope vaccine is a promising prophylactic candidate against RVFV pathogenesis.">
            <meta name="dc.subject" content="Vaccine Design, Immunoinformatics, Rift Valley fever virus, Immune Simulation">
            <meta name="dc.creator" content="Bhuiyan, Maruf Ahmed">
            <meta name="dc.creator" content="Quayum, Syeda Tasnim">
            <meta name="dc.creator" content="Ahammad, Foysal">
            <meta name="dc.creator" content="Alam, Rahat">
            <meta name="dc.creator" content="Samad, Abdus">
            <meta name="dc.creator" content="Nain, Zulkar">
            <meta name="dc.date" content="2020/08/18">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.24975.1">
            <meta name="dc.source" content="F1000Research 2020 9:999">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="Vaccine Design">
            <meta name="prism.keyword" content="Immunoinformatics">
            <meta name="prism.keyword" content="Rift Valley fever virus">
            <meta name="prism.keyword" content="Immune Simulation">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2020/08/18">
            <meta name="prism.volume" content="9">
            <meta name="prism.number" content="999">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.24975.1">
            <meta name="prism.url" content="https://f1000research.com/articles/9-999">
            <meta name="citation_title" content="Discovery of potential immune epitopes and peptide vaccine design - a prophylactic strategy against Rift Valley fever&lt;i&gt; &lt;/i&gt;virus">
            <meta name="citation_abstract" content=" Background: Rift Valley fever virus (RVFV) is an emerging arbovirus infecting both animals and humans. Any form of direct contact with body fluids, blood or tissue of infected animals is the mode of transmission of this pathogen. Despite being an emerging virus, no proper vaccinations are yet available for the public. Our objective is to compose a multiepitope vaccine utilizing immuno-bioinformatics as a strategy against RVFV. 
 Methods: To identify immunodominant epitopes and design a potent vaccine candidate, we applied a series of immunoinformatic approaches with molecular dynamics and immune response simulation frameworks. 
 Results: A glycoprotein with the highest antigenicity was selected and employed for determining promising epitopes. We selected T cell epitopes based on their immunological potencies and cytokine inducing properties, while B cell epitopes were selected based on their antigenic features. Finally, we selected four cytotoxic T-lymphocyte, two helper T-lymphocyte, and three linear B-lymphocyte epitopes that were arranged into a vaccine construct with appropriate adjuvants and linkers. The chimera protein was modeled, refined, and validated prior to docking against toll-like receptor 4. Docking studies suggest strong binding interactions while dynamics simulation revealed the stable nature of the docked complex. Furthermore, the immune simulation showed robust and prolonged immune responses with rapid antigen clearance. Finally, codon optimization and cloning conducted with Escherichia coli K12 suggests high translation efficiency within the host system. 
 Conclusion: We believe that our designed multiepitope vaccine is a promising prophylactic candidate against RVFV pathogenesis.">
            <meta name="citation_description" content=" Background: Rift Valley fever virus (RVFV) is an emerging arbovirus infecting both animals and humans. Any form of direct contact with body fluids, blood or tissue of infected animals is the mode of transmission of this pathogen. Despite being an emerging virus, no proper vaccinations are yet available for the public. Our objective is to compose a multiepitope vaccine utilizing immuno-bioinformatics as a strategy against RVFV. 
 Methods: To identify immunodominant epitopes and design a potent vaccine candidate, we applied a series of immunoinformatic approaches with molecular dynamics and immune response simulation frameworks. 
 Results: A glycoprotein with the highest antigenicity was selected and employed for determining promising epitopes. We selected T cell epitopes based on their immunological potencies and cytokine inducing properties, while B cell epitopes were selected based on their antigenic features. Finally, we selected four cytotoxic T-lymphocyte, two helper T-lymphocyte, and three linear B-lymphocyte epitopes that were arranged into a vaccine construct with appropriate adjuvants and linkers. The chimera protein was modeled, refined, and validated prior to docking against toll-like receptor 4. Docking studies suggest strong binding interactions while dynamics simulation revealed the stable nature of the docked complex. Furthermore, the immune simulation showed robust and prolonged immune responses with rapid antigen clearance. Finally, codon optimization and cloning conducted with Escherichia coli K12 suggests high translation efficiency within the host system. 
 Conclusion: We believe that our designed multiepitope vaccine is a promising prophylactic candidate against RVFV pathogenesis.">
            <meta name="citation_keywords" content="Vaccine Design, Immunoinformatics, Rift Valley fever virus, Immune Simulation">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Maruf Ahmed Bhuiyan">
            <meta name="citation_author_institution" content="Department of Virology, Bangabandhu Sheikh Mujib Medical University, Dhaka, 1000, Bangladesh">
            <meta name="citation_author" content="Syeda Tasnim Quayum">
            <meta name="citation_author_institution" content="Department Biochemistry and Microbiology, North South University, Bashundhara, Dhaka, 1229, Bangladesh">
            <meta name="citation_author" content="Foysal Ahammad">
            <meta name="citation_author_institution" content="Department of Biological Sciences, Faculty of Science, King Abdulaziz University, Jeddah, 21589, Saudi Arabia">
            <meta name="citation_author_institution" content="Biological Solution Centre (BioSol Centre), Farmgate, Dhaka, 1215, Bangladesh">
            <meta name="citation_author" content="Rahat Alam">
            <meta name="citation_author_institution" content="Department of Genetic Engineering and Biotechnology, Faculty of Biological Science and Technology, Jashore University of Science and Technology, Jashore, 7408, Bangladesh">
            <meta name="citation_author_institution" content="Biological Solution Centre (BioSol Centre), Farmgate, Dhaka, 1215, Bangladesh">
            <meta name="citation_author" content="Abdus Samad">
            <meta name="citation_author_institution" content="Department of Genetic Engineering and Biotechnology, Faculty of Biological Science and Technology, Jashore University of Science and Technology, Jashore, 7408, Bangladesh">
            <meta name="citation_author_institution" content="Biological Solution Centre (BioSol Centre), Farmgate, Dhaka, 1215, Bangladesh">
            <meta name="citation_author" content="Zulkar Nain">
            <meta name="citation_author_institution" content="Department of Biotechnology and Genetic Engineering, Faculty of Biological Sciences, Islamic University, Kushtia, 7003, Bangladesh">
            <meta name="citation_author_institution" content="Department of Genetic Engineering and Biotechnology, Faculty of Sciences and Engineering, East West University, Dhaka, 1212, Bangladesh">
            <meta name="citation_author_institution" content="Biological Solution Centre (BioSol Centre), Farmgate, Dhaka, 1215, Bangladesh">
            <meta name="citation_publication_date" content="2020/08/18">
            <meta name="citation_volume" content="9">
            <meta name="citation_publication_number" content="999">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.24975.1">
            <meta name="citation_firstpage" content="999">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/9-999/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/9-999.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=27552 /> <input type=hidden id=articleId name=articleId value=24975 /> <input type=hidden id=xmlUrl value="/articles/9-999/v1/xml"/> <input type=hidden id=xmlFileName value="-9-999-v1.xml"> <input type=hidden id=article_uuid value=53281b1e-d39a-4533-9629-211bb1c9d578 /> <input type=hidden id=referer value=""/> <input type="hidden" id="meta-article-title" value="Discovery of potential immune epitopes and peptide vaccine design - a prophylactic strategy against Rift Valley fever<i> </i>virus" /> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.24975.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.24975.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/9-999"
  },
  "headline": "Discovery of potential immune epitopes and peptide vaccine design - a prophylactic strategy against Rift...",
  "datePublished": "2020-08-18T15:55:34",
  "dateModified": "2020-08-18T15:55:34",
  "author": [
    {
      "@type": "Person",
      "name": "Maruf Ahmed Bhuiyan"
    },    {
      "@type": "Person",
      "name": "Syeda Tasnim Quayum"
    },    {
      "@type": "Person",
      "name": "Foysal Ahammad"
    },    {
      "@type": "Person",
      "name": "Rahat Alam"
    },    {
      "@type": "Person",
      "name": "Abdus Samad"
    },    {
      "@type": "Person",
      "name": "Zulkar Nain"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Background: Rift Valley fever virus (RVFV) is an emerging arbovirus infecting both animals and humans. Any form of direct contact with body fluids, blood or tissue of infected animals is the mode of transmission of this pathogen. Despite being an emerging virus, no proper vaccinations are yet available for the public. Our objective is to compose a multiepitope vaccine utilizing immuno-bioinformatics as a strategy against RVFV.
Methods: To identify immunodominant epitopes and design a potent vaccine candidate, we applied a series of immunoinformatic approaches with molecular dynamics and immune response simulation frameworks.
Results: A glycoprotein with the highest antigenicity was selected and employed for determining promising epitopes. We selected T cell epitopes based on their immunological potencies and cytokine inducing properties, while B cell epitopes were selected based on their antigenic features. Finally, we selected four cytotoxic T-lymphocyte, two helper T-lymphocyte, and three linear B-lymphocyte epitopes that were arranged into a vaccine construct with appropriate adjuvants and linkers. The chimera protein was modeled, refined, and validated prior to docking against toll-like receptor 4. Docking studies suggest strong binding interactions while dynamics simulation revealed the stable nature of the docked complex. Furthermore, the immune simulation showed robust and prolonged immune responses with rapid antigen clearance. Finally, codon optimization and cloning conducted with Escherichia coli K12 suggests high translation efficiency within the host system.
Conclusion: We believe that our designed multiepitope vaccine is a promising prophylactic candidate against RVFV pathogenesis."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/9-999/v1",
            "name": "Discovery of potential immune epitopes and peptide vaccine design..."
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Discovery of potential immune epitopes and peptide vaccine design... </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=27552 data-id=24975 data-downloads="" data-views="" data-scholar="10.12688/f1000research.24975.1" data-recommended="" data-doi="10.12688/f1000research.24975.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/9-999/v1/pdf?article_uuid=53281b1e-d39a-4533-9629-211bb1c9d578" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-24975-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-24975-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-24975-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Bhuiyan MA, Quayum ST, Ahammad F <em>et al.</em> Discovery of potential immune epitopes and peptide vaccine design - a prophylactic strategy against Rift Valley fever<i> </i>virus [version 1; peer review: awaiting peer review]</span>. <i>F1000Research</i> 2020, <b>9</b>:999 (<a class=new-orange href="https://doi.org/10.12688/f1000research.24975.1" target=_blank>https://doi.org/10.12688/f1000research.24975.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-24975-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=24975 id=track-article-signin-24975 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/24975?target=/articles/9-999/v1">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=27552 /> <input name=articleId type=hidden value=24975 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Research Article </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Discovery of potential immune epitopes and peptide vaccine design - a prophylactic strategy against Rift Valley fever<i> </i>virus</h1><span class=other-info> [version 1; peer review: awaiting peer review]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class="">Maruf Ahmed Bhuiyan<a href="https://orcid.org/0000-0003-4783-8735" target=_blank id=author-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0003-4783-8735</div><sup>1</sup>,&nbsp;</span><span class="">Syeda Tasnim Quayum<a href="https://orcid.org/0000-0003-3615-8101" target=_blank id=author-orcid-1><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-1><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0003-3615-8101</div><sup>2</sup>,&nbsp;</span><span class="">Foysal Ahammad<a href="https://orcid.org/0000-0001-7313-4729" target=_blank id=author-orcid-2><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-2><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0001-7313-4729</div><sup>3,4</sup>,&nbsp;</span><span class="">Rahat Alam<sup>4,5</sup>,&nbsp;</span><span class=""><a href="mailto:kazisamad50@gmail.com" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Abdus Samad</span></a><a href="https://orcid.org/0000-0003-4336-5600" target=_blank id=author-orcid-4><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-4><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0003-4336-5600</div><sup>4,5</sup>,&nbsp;</span><span class=""><a href="mailto:znain.bd@gmail.com" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Zulkar Nain</span></a><a href="https://orcid.org/0000-0003-0819-3137" target=_blank id=author-orcid-5><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-5><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0003-0819-3137</div><sup>4,6,7</sup></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class="">Maruf Ahmed Bhuiyan<a href="http://orcid.org/0000-0003-4783-8735" target=_blank id=mauthor-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0003-4783-8735</div><sup>1</sup>,&nbsp;</span><span class="">Syeda Tasnim Quayum<a href="http://orcid.org/0000-0003-3615-8101" target=_blank id=mauthor-orcid-1><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-1><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0003-3615-8101</div><sup>2</sup>,&nbsp;</span><a href="#" class=article-page-expand-authors>[...]&nbsp;</a><span class=article-page-hidden-authors>Foysal Ahammad<a href="http://orcid.org/0000-0001-7313-4729" target=_blank id=mauthor-orcid-2><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-2><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0001-7313-4729</div><sup>3,4</sup>,&nbsp;</span><span class=article-page-hidden-authors>Rahat Alam<sup>4,5</sup>,&nbsp;</span><span class=""><a href="mailto:kazisamad50@gmail.com" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Abdus Samad</span></a><a href="http://orcid.org/0000-0003-4336-5600" target=_blank id=mauthor-orcid-4><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-4><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0003-4336-5600</div><sup>4,5</sup>,&nbsp;</span><span class=""><a href="mailto:znain.bd@gmail.com" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Zulkar Nain</span></a><a href="http://orcid.org/0000-0003-0819-3137" target=_blank id=mauthor-orcid-5><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-5><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0003-0819-3137</div><sup>4,6,7</sup></span><span class="author-display-control article-page-expand-authors f1r-icon icon-20_plus_big"></span><span class="author-display-control article-page-hidden-authors f1r-icon icon-12_minus_big"></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 18 Aug 2020 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.24975.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Department of Virology, Bangabandhu Sheikh Mujib Medical University, Dhaka, 1000, Bangladesh<br/> <sup>2</sup> Department Biochemistry and Microbiology, North South University, Bashundhara, Dhaka, 1229, Bangladesh<br/> <sup>3</sup> Department of Biological Sciences, Faculty of Science, King Abdulaziz University, Jeddah, 21589, Saudi Arabia<br/> <sup>4</sup> Biological Solution Centre (BioSol Centre), Farmgate, Dhaka, 1215, Bangladesh<br/> <sup>5</sup> Department of Genetic Engineering and Biotechnology, Faculty of Biological Science and Technology, Jashore University of Science and Technology, Jashore, 7408, Bangladesh<br/> <sup>6</sup> Department of Genetic Engineering and Biotechnology, Faculty of Sciences and Engineering, East West University, Dhaka, 1212, Bangladesh<br/> <sup>7</sup> Department of Biotechnology and Genetic Engineering, Faculty of Biological Sciences, Islamic University, Kushtia, 7003, Bangladesh<br/> <p> <div class=margin-bottom> Maruf Ahmed Bhuiyan <br/> <span>Roles: </span> Data Curation, Formal Analysis, Investigation, Visualization, Writing – Original Draft Preparation </div> <div class=margin-bottom> Syeda Tasnim Quayum <br/> <span>Roles: </span> Formal Analysis, Investigation, Visualization, Writing – Original Draft Preparation </div> <div class=margin-bottom> Foysal Ahammad <br/> <span>Roles: </span> Resources, Writing – Review & Editing </div> <div class=margin-bottom> Rahat Alam <br/> <span>Roles: </span> Formal Analysis, Investigation, Visualization </div> <div class=margin-bottom> Abdus Samad <br/> <span>Roles: </span> Methodology, Resources, Supervision, Writing – Review & Editing </div> <div class=margin-bottom> Zulkar Nain <br/> <span>Roles: </span> Conceptualization, Methodology, Supervision, Validation, Writing – Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <em>AWAITING PEER REVIEW</em> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> <b>Background:</b> Rift Valley fever virus (RVFV) is an emerging arbovirus infecting both animals and humans. Any form of direct contact with body fluids, blood or tissue of infected animals is the mode of transmission of this pathogen. Despite being an emerging virus, no proper vaccinations are yet available for the public. Our objective is to compose a multiepitope vaccine utilizing immuno-bioinformatics as a strategy against RVFV.<br/> <b>Methods:</b> To identify immunodominant epitopes and design a potent vaccine candidate, we applied a series of immunoinformatic approaches with molecular dynamics and immune response simulation frameworks.<br/> <b>Results:</b> A glycoprotein with the highest antigenicity was selected and employed for determining promising epitopes. We selected T cell epitopes based on their immunological potencies and cytokine inducing properties, while B cell epitopes were selected based on their antigenic features. Finally, we selected four cytotoxic T-lymphocyte, two helper T-lymphocyte, and three linear B-lymphocyte epitopes that were arranged into a vaccine construct with appropriate adjuvants and linkers. The chimera protein was modeled, refined, and validated prior to docking against toll-like receptor 4. Docking studies suggest strong binding interactions while dynamics simulation revealed the stable nature of the docked complex. Furthermore, the immune simulation showed robust and prolonged immune responses with rapid antigen clearance. Finally, codon optimization and cloning conducted with <i>Escherichia coli </i>K12 suggests high translation efficiency within the host system.<br/> <b>Conclusion:</b> We believe that our designed multiepitope vaccine is a promising prophylactic candidate against RVFV pathogenesis. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> Vaccine Design, Immunoinformatics, Rift Valley fever virus, Immune Simulation </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Abdus Samad (<a href="mailto:kazisamad50@gmail.com">kazisamad50@gmail.com</a>) <br> Zulkar Nain (<a href="mailto:znain.bd@gmail.com">znain.bd@gmail.com</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding authors:</b> Abdus Samad, Zulkar Nain </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> No competing interests were disclosed. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The author(s) declared that no grants were involved in supporting this work. </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2020 Bhuiyan MA <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Bhuiyan MA, Quayum ST, Ahammad F <em>et al.</em> Discovery of potential immune epitopes and peptide vaccine design - a prophylactic strategy against Rift Valley fever<i> </i>virus [version 1; peer review: awaiting peer review]</span>. <i>F1000Research</i> 2020, <b>9</b>:999 (<a href="https://doi.org/10.12688/f1000research.24975.1" target=_blank>https://doi.org/10.12688/f1000research.24975.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 18 Aug 2020, <b>9</b>:999 (<a href="https://doi.org/10.12688/f1000research.24975.1" target=_blank>https://doi.org/10.12688/f1000research.24975.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 18 Aug 2020, <b>9</b>:999 (<a href="https://doi.org/10.12688/f1000research.24975.1" target=_blank>https://doi.org/10.12688/f1000research.24975.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d5014e283>Abbreviations</h2><p class="" id=d5014e286>2D, two-dimensional; 3D, three-dimensional; ACC, auto cross co-variance; CAI, codon adaptation index; CTL, cytotoxic T-lymphocyte; <i>E. coli</i>, <i>Escherichia coli</i>; GC, guanine and cytosine; GRAVY, grand average of hydropathicity; HTL, helper T-lymphocyte; IEDB, immune epitope database; IFN, interferon; IFN-γ, interferon-gamma; IL, interleukin; IL-10, interleukin 10; IL-4, interleukin 4; kNN, k-nearest neighbors; LBL, linear B-lymphocyte; MHC, major histocompatibility complex; NCBI, National Center for Biotechnology Information; NMA, normal mode analysis; PDB, Protein Data Bank; PI, isoelectric point; RMSD, root mean square deviation; RVF, Rift Valley fever; RVFV, Rift Valley fever virus; SVM, support vector machine; TAP, transporter associated with antigen processing; TLR4, toll-like receptor 4. </p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d5014e298>Introduction</h2><p class="" id=d5014e301>Rift Valley fever virus (RVFV) is a risk to worldwide public health and farming, especially in parts of Africa, Madagascar, and the Middle East<sup><a href="#ref-1">1</a></sup>. RVFV epidemics have killed hundreds of thousands of animals, more than a thousand humans, and caused significant economic losses<sup><a href="#ref-2">2</a></sup>. RVFV is a negative sense, single-stranded RNA (ssRNA) virus<sup><a href="#ref-3">3</a></sup> and belongs to the family of <i>Bunyaviridae</i>. RVFV was first identified in Kenya among sheep, in the vicinity of Lake Naivasha<sup><a href="#ref-4">4</a></sup>. Using mosquitoes as a vector it can cause large scale transmission, causing mild symptoms like fever, back pain and nausea to fatal illnesses including critical eye diseases, encephalitis in humans, and lethal hemorrhage in animals<sup><a href="#ref-5">5</a></sup>. Mortality of up to 90% has been reported in newborn animals and up to 30% in adult animals<sup><a href="#ref-6">6</a></sup>, although the mortality rate for humans has been reported to be approximately 2%<sup><a href="#ref-7">7</a></sup>. Epidemic alarms have persuaded several national and international health organizations to issue cautions about the rising risk of infection in Rift Valley fever (RVF) uninfected countries, like Europe and USA, due to the existence of vectors of transmission which are highly permissive, further compounded by global animal trade<sup><a href="#ref-7">7</a>–<a href="#ref-9">9</a></sup>. These reports unanimously concluded that coordinated efforts are needed in order to prepare for preventive measures against the recurrent emergence of RVFV.</p><p class="" id=d5014e343>RVF is an arthropod-borne zoonotic infectious viral disease caused by RVFV<sup><a href="#ref-9">9</a></sup>. Direct contact via tissue, body fluids or blood of RVFV infected animals acts as the prime mode of transmission for humans<sup><a href="#ref-10">10</a></sup>. Mosquitoes are a major vector for RVFV spread<sup><a href="#ref-11">11</a></sup>, infecting humans over long distances and even causing vertical transmission between livestock<sup><a href="#ref-8">8</a></sup>. The incubation period for RVFV is about 2–6 days in humans. The virus consists of a negative sense, triple segmented (large, medium, and small) ssRNA molecule and has a viral genome encoding four proteins: glycoprotein, RNA-dependent RNA polymerase, non-structural protein, and nucleocapsid protein<sup><a href="#ref-12">12</a>–<a href="#ref-14">14</a></sup>. Although the non-structural proteins facilitate RVF to survive inside its host by inhibiting first-line immunogenic responses, its glycoproteins are essential and highly crucial for invasion, entry and viral replication inside the host cell<sup><a href="#ref-13">13</a>,<a href="#ref-14">14</a></sup>. Thus, the viral glycoproteins were targeted for our multiepitope vaccine design, which would be constructed using glycoprotein epitope sequences evoking an immune response inside the human system<sup><a href="#ref-13">13</a>,<a href="#ref-14">14</a></sup>. At present, epitope-based candidate vaccine design against viruses and bacteria as well as parasites has become very popular and has been done previously<sup><a href="#ref-15">15</a>–<a href="#ref-20">20</a></sup>. Multiepitope vaccines consist of short peptide fragments of immunogenic stimulants, which trigger a strong immune response and allow for a significantly lower chance of allergenic reactions inside the host system<sup><a href="#ref-21">21</a></sup>. The identification of immunogenic epitopes derived from viral glycoprotein or nucleocapsid sequences has significantly enhanced the <i>in silico</i> development of peptide vaccines<sup><a href="#ref-22">22</a></sup>.</p><p class="" id=d5014e402>In our study, we screened the RVFV proteome to find the highest antigenic glycoprotein to predict T and B cell epitopes using a computational approach. Subsequently, cytotoxic T-lymphocyte (CTL), helper T-lymphocyte (HTL) and linear B-lymphocyte (LBL) epitopes predicted to be immunogenic and antigenic were shortlisted, which were further subjected to toxicity and allergenicity analysis. A vaccine design was assembled by combining all the assessed CTL, HTL and LBL epitopes using linkers and an appropriate adjuvant. Physicochemical analysis and solubility prediction were performed in <i>Escherichia coli</i> (<i>E. coli</i>) to assess the vaccine. Next, secondary and tertiary vaccine models were predicted using structure analysis tools. The predicted tertiary structure was refined and validated. Moreover, a disulfide bond was introduced by disulfide engineering, improving vaccine stability. Interactions within the vaccine-TLR4 complex were studied using molecular docking and evaluated using molecular dynamics simulation. Additionally, codon optimization was carried out to increase the translation efficiency of the designed vaccine within a <i>E. coli</i> K12 host. Finally, immune simulation was carried out to predict real-life immunogenic potency of the vaccine. The employed steps for the development of vaccine are summarized in <a href="#f1">Figure 1</a>.</p><a name=f1 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/27552/11a59d69-be6e-4f40-a6ca-41603d4df484_figure1.gif"><img alt="11a59d69-be6e-4f40-a6ca-41603d4df484_figure1.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/27552/11a59d69-be6e-4f40-a6ca-41603d4df484_figure1.gif"></a><div class=caption><h3>Figure 1. Flowchart representing the overall vaccine design process from designing to validation and simulation <i>in silico</i>.</h3><p id=d5014e430>LBL, linear B-lymphocyte; HTL, helper T-lymphocyte; CTL, cytotoxic T-lymphocyte.</p></div></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d5014e440>Methods</h2><div class=section><a name=d5014e443 class=n-a></a><h3 class=section-title>Proteome collection and antigenicity evaluation</h3><p class="" id=d5014e448>The 232 complete proteomes of RVFV were obtained from <a target=xrefwindow href="https://www.viprbrc.org/brc/" id=d5014e450>ViPR (Virus Pathogen Resource) database</a> (Supplementary Table 1, <i>Extended data</i>)<sup><a href="#ref-23">23</a></sup>. ViPR is a reliable and open database for pathogenic virus families<sup><a href="#ref-24">24</a></sup>. The viral proteome sequences retrieved were evaluated using <a target=xrefwindow href="http://www.ddg-pharmfac.net/vaxijen/VaxiJen/VaxiJen.html" id=d5014e464>VaxiJen v2.0 server</a> for scores indicating antigenic influence. The threshold for antigenicity was fixed at 0.5<sup><a href="#ref-25">25</a></sup>. VaxiJen v2.0 sever possesses high prediction powers and utilizes auto cross-covariance (ACC) transformation methods. The glycoprotein sequence with the highest antigenicity score was taken from this proteome for further analysis.</p></div><div class=section><a name=d5014e474 class=n-a></a><h3 class=section-title>CTL epitopes and their MHC class I alleles predictions</h3><p class="" id=d5014e479>the <a target=xrefwindow href="http://www.cbs.dtu.dk/services/NetCTL/" id=d5014e481>NetCTL v1.2 tool</a> was utilized to isolate CTL peptides from the RVF glycoprotein sequence. This server generates different nonamer epitopes against 12 supertypes (A1, A2, A3, A24, A26, B7, B8, B27, B39, B44, B58, B62). NetCTL v1.2 identifies CTL epitopes depending on C-terminal cleavage, TAP competence and MHC-1 complex binding<sup><a href="#ref-26">26</a></sup>. The threshold was determined at 0.5 with a corresponding sensitivity of 0.89 and specificity of 0.94. The MHC-I affinity for the CTL peptides was identified using the <a target=xrefwindow href="http://tools.immuneepitope.org/mhci/" id=d5014e488>MHC-I IEDB web server</a><sup><a href="#ref-27">27</a></sup> and a consensus percentile of ≤5 was set to narrow down CTL epitopes, for obtaining high-affinity epitopes with MHC-1 alleles.</p></div><div class=section><a name=d5014e496 class=n-a></a><h3 class=section-title>Assessment of CTL epitopes</h3><p class="" id=d5014e501>The isolated CTL epitopes were assessed for antigenicity by submitting them to the VaxiJen v2.0 server. To ensure proper induction of immune response in the human body, the immunogenicity of these epitopes was evaluated using the <a target=xrefwindow href="http://tools.iedb.org/immunogenicity/" id=d5014e503>IEDB Immunogenicity tool</a><sup><a href="#ref-28">28</a></sup>. Furthermore, <a target=xrefwindow href="https://www.ddg-pharmfac.net/AllerTOP/" id=d5014e509>AllerTOP v2.0 server</a> was chosen for predicting allergenicity and ensure that the vaccine construct does not induce an allergic reaction in humans. AllerTOP v.2.0 uses k-nearest neighbors (kNN) methods to distinguish allergens from non-allergens<sup><a href="#ref-29">29</a></sup>. Lastly, the selected nonamers were screened for probable toxicity using <a target=xrefwindow href="http://crdd.osdd.net/raghava/toxinpred/" id=d5014e516>ToxinPred server</a>, which predicts toxic epitopes using quantitative matrix methods and machine learning technology<sup><a href="#ref-30">30</a></sup>.</p></div><div class=section><a name=d5014e525 class=n-a></a><h3 class=section-title>Identification of HTL epitopes and binding MHC class II alleles</h3><p class="" id=d5014e530>HTL acts as the orchestrator to stimulate B cells, macrophages, and CD8+ cells to fight against pathogens. Consequently, HTL epitopes are important for making an effective vaccine<sup><a href="#ref-31">31</a></sup>. HTL epitopes, each 15-mer in length, were identified by utilizing the <a target=xrefwindow href="http://tools.iedb.org/mhcii/" id=d5014e536>IEDB MHC-II tool</a>. The anticipation of binding of the epitopes to class II alleles, HLA-DP, HLA-DR and HLA-DQ, were determined utilizing the consensus 2.22 prediction method on the same server<sup><a href="#ref-32">32</a></sup>. Due to obtaining a large number of epitopes, a percentile rank of ≤0.3 was set as a threshold.</p></div><div class=section><a name=d5014e546 class=n-a></a><h3 class=section-title>Selection of cytokine-inducing HTL epitopes</h3><p class="" id=d5014e551>HTLs release cytokines such as interferon-gamma (IFN-γ), interleukin 4 (IL-4), and interleukin 10 (IL-10) that can activate immune cells in the body. In addition, cytokines released by HTLs can survive past inflammatory responses and avert tissue damage. Therefore, HTL epitopes that can induce the release of cytokines are important in vaccine development. Therefore, in order to incorporate the epitopes that induce IFN- γ, we used the <a target=xrefwindow href="http://crdd.osdd.net/raghava/ifnepitope/predict.php" id=d5014e553>IFNepitope server</a>, through the hybrid method (motif and SVM)<sup><a href="#ref-33">33</a></sup>. Furthermore, the peptides were evaluated to check if they induce IL-4 and IL-10 using <a target=xrefwindow href="http://crdd.osdd.net/raghava/il4pred/design.php" id=d5014e560>IL4pred</a> and <a target=xrefwindow href="https://webs.iiitd.edu.in/raghava/il10pred/predict3.php" id=d5014e563>IL10pred</a> servers, respectively<sup><a href="#ref-34">34</a>,<a href="#ref-35">35</a></sup>.</p></div><div class=section><a name=d5014e575 class=n-a></a><h3 class=section-title>Evaluation of LBL epitopes</h3><p class="" id=d5014e580>The activation of B cells plays a vital part in the activation of the humoral immune response and generation of plasma cells against a specific antigen, and distinguishing LBL epitopes is another vital step in the development of epitope-based vaccine constructs. LBL epitopes were predicted using a combinatorial algorithm of gradient boosting and a randomized tree method using the <a target=xrefwindow href="http://www.thegleelab.org/iBCE-EL/iBCE.html" id=d5014e582>iBCE-EL server</a><sup><a href="#ref-36">36</a></sup>. The predicted LBL epitopes were then reevaluated for their antigenicity score with VaxiJen v2.0 server, and non-allergenic and non-toxic epitopes were predicted using the AllerTOP v2.0 server and ToxinPred tool, respectively.</p></div><div class=section><a name=d5014e590 class=n-a></a><h3 class=section-title>Estimation of population coverage</h3><p class="" id=d5014e595>For an epitope to be antigenic and evoke a strong immune reaction it needs to be acknowledged by the MHC complex molecule. MHC alleles are the most polymorphic and occur in thousands of HLA combinations in humans. Therefore, an HLA allele with a high frequency of occurrences in the majority population of the world would have a high chance of exerting an effect immunogenic<sup><a href="#ref-37">37</a></sup>. In our study, we wanted to find out the distribution, presence and frequency of the T cell epitopes, which were selected for the purpose of designing the vaccine structure. Allele Population Coverage of <a target=xrefwindow href="http://tools.iedb.org/population/" id=d5014e601>IEDB population coverage tool</a> was utilized for the calculation of population coverage<sup><a href="#ref-38">38</a></sup>. A prediction analysis was run on regions of Africa where the RVFV outbreak initially started and the neighboring countries that were mostly affected and also across the entire world.</p></div><div class=section><a name=d5014e610 class=n-a></a><h3 class=section-title>Assembling of multiepitope vaccine</h3><p class="" id=d5014e615>All the predicted and assessed epitopes i.e. CTL, LBL, and HTL peptides were joined together using linkers and an adjuvant sequence was added upstream of all of them to form a vaccine structure. 50S ribosomal protein L7/L12 (GenPept Accession: <a target=xrefwindow href="https://www.ncbi.nlm.nih.gov/protein/P9WHE3" id=d5014e617>P9WHE3</a>) is a toll-like receptor 4 (TLR4) agonist and was chosen as an adjuvant for the construct to boost the immune response against it<sup><a href="#ref-21">21</a></sup>. TLR4 can recognize viral glycoproteins and bacterial ligands<sup><a href="#ref-39">39</a>,<a href="#ref-40">40</a></sup> stimulates the production of cytokines against them<sup><a href="#ref-41">41</a></sup>. The CTL peptides and the 50S L7/L12 protein adjuvant were linked together with the EAAAK linker to ensure adequate separation between each component for their effective interaction with their respective targets. This linker was chosen as it separates bifunctional fused protein domains<sup><a href="#ref-42">42</a></sup>. Each CTL epitope was separated using AAY linkers, and HTL epitopes by GPGPG linkers. Independent immunogenic potential of each LBL epitope was preserved by separating them using KK linkers<sup><a href="#ref-43">43</a></sup>.</p></div><div class=section><a name=d5014e646 class=n-a></a><h3 class=section-title>Host homology crosschecking</h3><p class="" id=d5014e651>To avoid the risk of elicitation of autoimmunity by molecular mimicry, we screened the vaccine construct against the <i>Homo sapiens</i> protein sequences (NCBI: txid9606) through the use of NCBI BLASTp<sup><a href="#ref-44">44</a></sup>.</p></div><div class=section><a name=d5014e662 class=n-a></a><h3 class=section-title>Physicochemical evaluation of the vaccine construct</h3><p class="" id=d5014e667>Vaccines are developed to provide protection against diseases by evoking an immune response after injection against specific antigens, without causing any disease. Thus, vaccines need to have antigen inducing capability without being allergenic to the receiver. Therefore, the multiepitope vaccine construct was tested for antigenicity and allergenicity in each step of the initial design, using VaxiJen v2.0<sup><a href="#ref-25">25</a></sup> and AllerTOP v2.0 servers, respectively<sup><a href="#ref-29">29</a></sup>. Predictive assessment of different physiochemical attributes of the subunit vaccine was carried out using the <a target=xrefwindow href="https://web.expasy.org/protparam/" id=d5014e677>ProtParam server</a><sup><a href="#ref-45">45</a></sup>. Lastly, the <a target=xrefwindow href="http://scratch.proteomics.ics.uci.edu/" id=d5014e683>SOLpro server</a> in the SCRATCH suite was utilized to assess the solubility of the vaccine structure in <i>E. coli</i>, with a view to determining the bioavailability of the vaccine<sup><a href="#ref-46">46</a></sup>.</p></div><div class=section><a name=d5014e697 class=n-a></a><h3 class=section-title>Secondary and tertiary modelling of the construct</h3><p class="" id=d5014e702>Predicted two dimensional (2D) configuration of our vaccine design was generated using the <a target=xrefwindow href="http://bioinf.cs.ucl.ac.uk/psipred/" id=d5014e704>PSIPRED v4.0 web tool</a>. The PSIPRED tool utilizes the query amino acid residues to predict a 2D model using two-feed-forward neural networking along with PSI-BLAST<sup><a href="#ref-47">47</a></sup>. The three dimensional (3D) model of our designed vaccine was attained through the <a target=xrefwindow href="https://zhanglab.ccmb.med.umich.edu/I-TASSER/" id=d5014e711>I-TASSER web tool</a>, which exhibits protein modeling via a hierarchical procedure to estimate and bring about suitable structure and function<sup><a href="#ref-48">48</a></sup>. The I-TASSER site helps to generate 3D structure of a protein and determine its functions using a state-of-the-art algorithm with high precision. This web tool enables determination of C-score, TM-score value and root mean square deviation (RMSD), along with the top five predicted structure models of the given protein sequence<sup><a href="#ref-48">48</a></sup>. The produced 3D structure was chosen based on its C-score value and downloaded in PDB format. The server provides a C-score ranging between -5 to 2, where a higher value indicates a better model<sup><a href="#ref-48">48</a></sup>.</p></div><div class=section><a name=d5014e729 class=n-a></a><h3 class=section-title>Refinement and verification of 3D vaccine</h3><p class="" id=d5014e734>Our 3D vaccine structure was refined using the <a target=xrefwindow href="http://galaxy.seoklab.org/cgi-bin/submit.cgi?type=REFINE" id=d5014e736>GalaxyRefine server</a>. The web-based program reconstructs sidechains, then repacks them using dynamic simulations for proper structural relaxation<sup><a href="#ref-49">49</a></sup>. The <a target=xrefwindow href="https://prosa.services.came.sbg.ac.at/prosa.php" id=d5014e743>ProSA tool</a> was used to recognize possible errors in the predicted tertiary model and for structural validation<sup><a href="#ref-16">16</a></sup>. If the calculated score of ProSA deviates from the given range, this indicates that the primary sequence and predicted structure possibly contain flaws<sup><a href="#ref-50">50</a></sup>. Additionally, the <a target=xrefwindow href="https://servicesn.mbi.ucla.edu/Verify3D/" id=d5014e755>Verify3D server </a>was employed to examine the congruity of a tertiary structure with its primary sequence. It is done by specifying a basic grade depending upon its position and surroundings and correlating the findings to known verified structures<sup><a href="#ref-51">51</a></sup>. Ramachandran plot generation was carried out using the <a target=xrefwindow href="http://mordred.bioc.cam.ac.uk/~rapper/rampage.php" id=d5014e762>RAMPAGE tool</a><sup><a href="#ref-52">52</a></sup>. The Ramachandran analysis plot is a visual representation of energetically permitted and rejected dihedral planar angles based on weak Van der Walls force of interactions between amino acids of the side chain. The RAMPAGE score enumerates the residues residing in favored, allowed and disallowed regions (in %) based on the PROCHECK principle<sup><a href="#ref-53">53</a></sup>.</p></div><div class=section><a name=d5014e774 class=n-a></a><h3 class=section-title>Disulfide bridging of vaccine</h3><p class="" id=d5014e779>Disulfide bonds are intra-protein bonds that can help stabilize tertiary or quaternary interactions in a protein<sup><a href="#ref-54">54</a></sup>. Therefore, disulfide engineering was accomplished by introducing two novel bonds in the vaccine framework by employing the <a target=xrefwindow href="http://cptweb.cpt.wayne.edu/DbD2/" id=d5014e785>Disulfide by Design v2.12 web tool</a>. The refined vaccine complex was uploaded, checked for a residue-pair match within parameters of χ3 angle -87° or +97° ± 30 and Cα-Cβ-Sγ angle 114.6° ± 10. Appropriate amino acid duos were chosen and mutated to cysteine residues<sup><a href="#ref-55">55</a></sup>.</p></div><div class=section><a name=d5014e794 class=n-a></a><h3 class=section-title>Codon optimization and <i>in silico</i> cloning</h3><p class="" id=d5014e802>Codon refinement is a vital step for the expression of the protein inside the host system. Therefore, codon adaptation was carried out by utilizing the <a target=xrefwindow href="http://www.jcat.de/" id=d5014e804>JCat web tool</a> in order to improve protein translation. <i>E</i>.<i>coli</i> K12 was selected for cloning since unadjusted codon sequences will reduce protein expression<sup><a href="#ref-56">56</a></sup>. Termination of transcription (rho-independent), prokaryotic ribosome region of attachment and restriction enzyme cut-off sites were disregarded by setting the parameters to “avoid”. The server further provided two additional measures such as the codon adaptation index (CAI) and GC content of the refined sequences<sup><a href="#ref-57">57</a></sup>. The codon nucleotide adapted sequence was cloned using SnapGene v5.0.8 software into a <i>E. coli</i> pET28a(+) vector obtained from SnapGene<sup><a href="#ref-58">58</a></sup>. <a target=xrefwindow href="https://www.piaggiogroup.com/en/brands/commercial-vehicles/ape" id=d5014e829>ApE</a> and <a target=xrefwindow href="http://www.genomecompiler.com/" id=d5014e832>Genome Compiler</a> are open access alternative to this software that could be used for this purpose.</p></div><div class=section><a name=d5014e837 class=n-a></a><h3 class=section-title>Molecular docking between TLR4 and vaccine</h3><p class="" id=d5014e842>Molecular docking is a computerized process that evaluates and assesses the contact between a protein and its receptor. The binding affinity and interaction between the proteins provide a simulated score<sup><a href="#ref-59">59</a></sup>. TLR4 can recognize viral glycoprotein<sup><a href="#ref-60">60</a></sup> and therefore, the TLR4 structure was obtained from PDB (PDB ID: <a target=xrefwindow href="https://identifiers.org/pdb:4G8A" id=d5014e852>4G8A</a>) and was chosen as a receptor to dock with the refined vaccine<sup><a href="#ref-61">61</a></sup>. <a target=xrefwindow href="https://cluspro.bu.edu/" id=d5014e859>ClusPro v2.0 web docking server</a> was appointed to determine the binding position and inclination for binding between the designed vaccine and TLR4 receptor<sup><a href="#ref-62">62</a></sup>. The vaccine-receptor composite was selected based on the binding position (on active site), docking efficiency and the lowest energy scoring of the docked complexes.</p></div><div class=section><a name=d5014e869 class=n-a></a><h3 class=section-title>Molecular dynamics simulation</h3><p class="" id=d5014e874>Determining the stability and firmness of the protein-receptor docked structure by molecular dynamics is essential for carrying out an <i>in silico</i> study. Protein stability was resolved by contrasting protein dynamics and their counterpart normal modes<sup><a href="#ref-63">63</a>,<a href="#ref-64">64</a></sup>. the <a target=xrefwindow href="http://imods.chaconlab.org/" id=d5014e886>iMODS tool</a> was used to evaluate and plot amino acid residues and their motion within their inner order via normal mode analysis (NMA)<sup><a href="#ref-65">65</a></sup>. The NMA tool surfaced the extent of motion of the vaccine-receptor complex in terms of covariance and ability to deform; along with eigenvalues and B-factor results. The deformability of the complex depends on whether it can rotate each of its residues while staying in its position. The eigenvalue demonstrates the rigidity of motion, being directly proportional to the energy required for the deformation of the structure. Lower eigenvalues represent easier structural deformation<sup><a href="#ref-65">65</a>,<a href="#ref-66">66</a></sup>.</p></div><div class=section><a name=d5014e903 class=n-a></a><h3 class=section-title>Estimation of immune response</h3><p class="" id=d5014e908>Simulations of immune response of the vaccine design were executed with the <a target=xrefwindow href="http://150.146.2.1/C-IMMSIM/index.php" id=d5014e910>C-IMMSIM v10.1 server</a>. This server uses position-specific scoring matrix (PSSM) and AI-based technology to predict the intensity of immune reaction caused by the multiepitope vaccine<sup><a href="#ref-67">67</a></sup>. It evaluates the immunologic response of the subunit vaccine according to an <i>in vivo</i> system and can also simulate immune response through its agent-based dynamic system. The minimum recommended interval is at least four weeks between the first and second dose<sup><a href="#ref-68">68</a></sup>. Time-steps for each vaccine dose were fixed: 1, 84 and finally 168 respectively, with an interval of eight hours in-between. Analysis of three doses was conducted in respect to immune cell rise and activity with at least four weeks in between each of the dose sessions.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d5014e929>Results</h2><div class=section><a name=d5014e932 class=n-a></a><h3 class=section-title>RVFV proteome and selected antigen</h3><p class="" id=d5014e937>Amino acid sequences of a total of 232 RVFV proteins were collected from the ViPR database. The VaxiJen v2.0 server revealed the two proteins with the highest antigenicity (<a href="#T1">Table 1</a>). The glycoprotein sequence was selected for further analysis.</p><a name=T1 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 1. Highest antigenic proteins of Rift Valley fever virus with antigenicity score, and amino acid length.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d5014e954 class=n-a></a><thead><a name=d5014e956 class=n-a></a><tr><a name=d5014e958 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d5014e960 class=n-a></a>Class</th><th align=left colspan=1 rowspan=1 valign=top><a name=d5014e963 class=n-a></a>Segment</th><th align=left colspan=1 rowspan=1 valign=top><a name=d5014e966 class=n-a></a>GenBank accession</th><th align=left colspan=1 rowspan=1 valign=top><a name=d5014e969 class=n-a></a>Length (AA)</th><th align=left colspan=1 rowspan=1 valign=top><a name=d5014e972 class=n-a></a>Antigenic score</th></tr></thead><tbody><a name=d5014e977 class=n-a></a><tr><a name=d5014e979 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e981 class=n-a></a>Non-structural</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e984 class=n-a></a>Segment: S</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e987 class=n-a></a><a target=xrefwindow href="https://www.ncbi.nlm.nih.gov/protein/AGB13810" id=d5014e988>AGB13810</a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e991 class=n-a></a>265</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e994 class=n-a></a>0.6010</td></tr><tr><a name=d5014e998 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1000 class=n-a></a>Glycoprotein</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1003 class=n-a></a>Segment: M</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1006 class=n-a></a><a target=xrefwindow href="https://www.ncbi.nlm.nih.gov/protein/AVK51661" id=d5014e1007>AVK51661</a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1010 class=n-a></a>1197</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1013 class=n-a></a>0.5277</td></tr></tbody></table></div></div><div class=section><a name=d5014e1021 class=n-a></a><h3 class=section-title>Potential CTL, HTL and LBL epitopes</h3><p class="" id=d5014e1026>NetCTL v1.2 server predicted 135 unique 9-mer CTL epitopes in total. Out of them, 27 epitopes were predicted as having the ability to act as both antigen and immunogen and were also nontoxic and nonallergenic (Supplementary Table 2, <i>Extended data</i>)<sup><a href="#ref-23">23</a></sup>. Only six CTL peptides were shortlisted for the ultimate vaccine design based on a combined score (<a href="#T2">Table 2</a>).</p><p class="" id=d5014e1039>Similarly, 182 15-mer HTL epitopes and their MHC-II binding alleles were predicted and evaluated by utilizing the IEDB MHC-II tool. Next, cytokine production capability of the selected HTL epitopes was predicted for IL-10, IL-4 and IFN-γ. Only 14 epitopes were found to be capable of inducing any of the three cytokines’ production and to have antigenicity (Supplementary Table 3, <i>Extended data</i>)<sup><a href="#ref-23">23</a></sup>. Of those that were capable of producing IFN-γ, two epitopes were chosen with the ability to produce IL-4 but not IL-10 and one epitope was chosen with the ability to produce IL-10 but not IL-4. Therefore, three epitopes were finally shortlisted prioritizing for IFN-γ and IL-4 production (<a href="#T3">Table 3</a>).</p><p class="" id=d5014e1052>B cells act as antigen-presenting cells that recognize epitopes present on a protein and can bring about a humoral immune response<sup><a href="#ref-69">69</a></sup>. The iBCE-EL sever program was used to predict unique LBL epitopes from the RVFV glycoprotein sequence. A total of 310 LBL epitopes were found. After further evaluation, 35 unique epitopes were found to be non-allergenic and non-toxic (Supplementary Table 4, <i>Extended data</i>)<sup><a href="#ref-23">23</a></sup>. Amidst those, only five LBL epitopes were chosen for vaccine construction based on iBCE-EL server’s probability scores. LBL epitopes with higher probability scores were chosen. (<a href="#T4">Table 4</a>).</p><a name=T2 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 2. Shortlisted cytotoxic T-lymphocyte epitopes for epitope-based peptide vaccine design.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d5014e1080 class=n-a></a><thead><a name=d5014e1082 class=n-a></a><tr><a name=d5014e1084 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d5014e1086 class=n-a></a>CTL epitope</th><th align=left colspan=1 rowspan=1 valign=top><a name=d5014e1089 class=n-a></a>C-score<sup> <a href="#tfn1">*</a> </sup> </th><th align=left colspan=1 rowspan=1 valign=top><a name=d5014e1098 class=n-a></a>Antigenicity</th><th align=left colspan=1 rowspan=1 valign=top><a name=d5014e1101 class=n-a></a>Immunogenicity</th><th align=left colspan=1 rowspan=1 valign=top><a name=d5014e1104 class=n-a></a>Allergenicity</th><th align=left colspan=1 rowspan=1 valign=top><a name=d5014e1108 class=n-a></a>Toxicity</th></tr></thead><tbody><a name=d5014e1113 class=n-a></a><tr><a name=d5014e1115 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1117 class=n-a></a>VFALAPVVF</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1120 class=n-a></a>1.7143</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1123 class=n-a></a>Yes</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1126 class=n-a></a>Yes</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1129 class=n-a></a>No</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1133 class=n-a></a>Non-Toxic</td></tr><tr><a name=d5014e1137 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1139 class=n-a></a> <b>STAHEVVPF</b> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1145 class=n-a></a> <b>1.7042</b> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1151 class=n-a></a> <b>Yes</b> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1157 class=n-a></a> <b>Yes</b> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1163 class=n-a></a> <b>No</b> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1170 class=n-a></a> <b>Non-Toxic</b> </td></tr><tr><a name=d5014e1177 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1179 class=n-a></a> <b>KLTLEITDF</b> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1185 class=n-a></a> <b>1.627</b> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1191 class=n-a></a> <b>Yes</b> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1197 class=n-a></a> <b>Yes</b> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1203 class=n-a></a> <b>No</b> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1210 class=n-a></a> <b>Non-Toxic</b> </td></tr><tr><a name=d5014e1217 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1219 class=n-a></a> <b>RDNETSAEF</b> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1225 class=n-a></a> <b>1.553</b> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1231 class=n-a></a> <b>Yes</b> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1237 class=n-a></a> <b>Yes</b> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1243 class=n-a></a> <b>No</b> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1250 class=n-a></a> <b>Non-Toxic</b> </td></tr><tr><a name=d5014e1257 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1259 class=n-a></a> <b>FSSVAIICL</b> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1265 class=n-a></a> <b>1.3561</b> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1271 class=n-a></a> <b>Yes</b> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1277 class=n-a></a> <b>Yes</b> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1283 class=n-a></a> <b>No</b> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1290 class=n-a></a> <b>Non-Toxic</b> </td></tr><tr><a name=d5014e1298 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1300 class=n-a></a>ALSIGLFFL</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1303 class=n-a></a>1.3051</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1306 class=n-a></a>Yes</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1309 class=n-a></a>Yes</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1312 class=n-a></a>No</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1316 class=n-a></a>Non-Toxic</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=tfn1 class=n-a></a><p id=d5014e1326> <sup>*</sup>C-score is the combined score provided by the NetCTL v1.2 server.</p></div></div></div><a name=T3 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 3. Shortlisted helper T-lymphocyte epitopes for epitope-based peptide vaccine design.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d5014e1347 class=n-a></a><thead><a name=d5014e1349 class=n-a></a><tr><a name=d5014e1351 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d5014e1353 class=n-a></a>HTL epitopes</th><th align=left colspan=1 rowspan=1 valign=top><a name=d5014e1356 class=n-a></a>Antigenicity</th><th align=left colspan=1 rowspan=1 valign=top><a name=d5014e1359 class=n-a></a>IFN-γ inducer</th><th align=left colspan=1 rowspan=1 valign=top><a name=d5014e1362 class=n-a></a>IL-4 inducer</th><th align=left colspan=1 rowspan=1 valign=top><a name=d5014e1365 class=n-a></a>IL-10 inducer</th></tr></thead><tbody><a name=d5014e1370 class=n-a></a><tr><a name=d5014e1372 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1374 class=n-a></a> <b>NTKCRLSGTALIRAG</b> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1380 class=n-a></a> <b>1.0947</b> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1386 class=n-a></a> <b>Positive</b> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1392 class=n-a></a> <b>IL4 inducer</b> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1398 class=n-a></a> <b>IL10 non-inducer</b> </td></tr><tr><a name=d5014e1405 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1407 class=n-a></a> <b>CNAGARVCLSITSTG</b> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1413 class=n-a></a> <b>1.115</b> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1419 class=n-a></a> <b>Positive</b> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1425 class=n-a></a> <b>IL4 inducer</b> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1431 class=n-a></a> <b>IL10 non-inducer</b> </td></tr><tr><a name=d5014e1438 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1440 class=n-a></a>TILLICLYVALSIGL</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1443 class=n-a></a>1.2038</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1446 class=n-a></a>Positive</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1449 class=n-a></a>Non-inducer</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1452 class=n-a></a>IL10 inducer</td></tr><tr><a name=d5014e1456 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1458 class=n-a></a>VVFVFSSVAIICLAI</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1461 class=n-a></a>1.108</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1464 class=n-a></a>Positive</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1467 class=n-a></a>Non-inducer</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1470 class=n-a></a>IL10 inducer</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=tfn2 class=n-a></a><p id=d5014e1480> IFN-γ, interferon gamma; IL-4, interleukin 4; IL-10, interleukin 10.</p></div></div></div><a name=T4 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 4. Shortlisted linear B-lymphocyte epitopes for epitope-based peptide vaccine design.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d5014e1497 class=n-a></a><thead><a name=d5014e1499 class=n-a></a><tr><a name=d5014e1501 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d5014e1503 class=n-a></a>LBL epitopes</th><th align=left colspan=1 rowspan=1 valign=top><a name=d5014e1506 class=n-a></a>Probability</th><th align=left colspan=1 rowspan=1 valign=top><a name=d5014e1509 class=n-a></a>Antigenicity</th><th align=left colspan=1 rowspan=1 valign=top><a name=d5014e1512 class=n-a></a>Allergenicity</th><th align=left colspan=1 rowspan=1 valign=top><a name=d5014e1515 class=n-a></a>Toxicity</th></tr></thead><tbody><a name=d5014e1520 class=n-a></a><tr><a name=d5014e1522 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1524 class=n-a></a>KGTMGSGQTKRE</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1527 class=n-a></a>0.8213</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1530 class=n-a></a>Antigen</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1533 class=n-a></a>Non-allergen</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1536 class=n-a></a>Non-Toxic</td></tr><tr><a name=d5014e1540 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1542 class=n-a></a> <b>PNDYQSAHYLNN</b> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1548 class=n-a></a> <b>0.8102</b> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1554 class=n-a></a> <b>Antigen</b> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1560 class=n-a></a> <b>Non-allergen</b> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1566 class=n-a></a> <b>Non-Toxic</b> </td></tr><tr><a name=d5014e1573 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1575 class=n-a></a> <b>PPKYELTEDCNF</b> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1581 class=n-a></a> <b>0.8043</b> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1587 class=n-a></a> <b>Antigen</b> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1593 class=n-a></a> <b>Non-allergen</b> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1599 class=n-a></a> <b>Non-Toxic</b> </td></tr><tr><a name=d5014e1606 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1608 class=n-a></a>VTGSQSPSTEIT</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1611 class=n-a></a>0.8042</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1614 class=n-a></a>Antigen</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1617 class=n-a></a>Non-allergen</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1620 class=n-a></a>Non-Toxic</td></tr><tr><a name=d5014e1624 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1626 class=n-a></a> <b>SLREEEMPEELS</b> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1632 class=n-a></a> <b>0.8039</b> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1638 class=n-a></a> <b>Antigen</b> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1644 class=n-a></a> <b>Non-allergen</b> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1650 class=n-a></a> <b>Non-Toxic</b> </td></tr></tbody></table></div></div><div class=section><a name=d5014e1661 class=n-a></a><h3 class=section-title>Estimated population coverage</h3><p class="" id=d5014e1666>The CTL and HTL epitopes across African regions and Southwest Asia have a mean population coverage of 77.39 %, with an average hit of 1.78. The total combined class 1 and 2 epitopes have significant coverage across Europe (99.92%), North America (100%), South America (99.39%) and South Asia (99%), which indicates the multiepitope vaccine would be a good candidate in eliciting an immune response in these worldwide regions. In the African population, where the initial outbreak began, there is good coverage in the majority of regions, except for South Africa (18.36%), as shown in <a href="#f2">Figure 2</a>.</p><a name=f2 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/27552/11a59d69-be6e-4f40-a6ca-41603d4df484_figure2.gif"><img alt="11a59d69-be6e-4f40-a6ca-41603d4df484_figure2.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/27552/11a59d69-be6e-4f40-a6ca-41603d4df484_figure2.gif"></a><div class=caption><h3>Figure 2. Population coverage with selected epitopes and their respective alleles.</h3></div></div></div><div class=section><a name=d5014e1687 class=n-a></a><h3 class=section-title>Epitope based subunit vaccine construct</h3><p class="" id=d5014e1692>To design our multiepitope vaccine, we picked four CTL epitopes (<a href="#T2">Table 2</a>) based on their high immunogenicity and antigenicity scores and which were non-allergic and nontoxic. For the HTL epitope selection, we looked for epitopes that could produce all three types of cytokine; however, no epitope was found that had the capacity to induce all three types of cytokines (IFN-γ, IL-10, and IL-4). Hence, only two HTL epitopes were chosen from the glycoprotein sequence, which were capable of inducing IFN-γ and IL-4 (<a href="#T3">Table 3</a>). Three LBL epitopes that were nontoxic and non-allergic and had the best iBCE-EL predicted probability, high antigenicity scores were selected (<a href="#T4">Table 4</a>). Two extra epitopes were shortlisted for each of the three cases for the purpose of randomization to find the optimum vaccine construct. The choice of adjuvant was 50S ribosomal protein L7/L12, retrieved from the NCBI Protein database (Accession no. <a target=xrefwindow href="https://www.ncbi.nlm.nih.gov/protein/P9WHE3" id=d5014e1703>P9WHE3</a>) and was linked to the selected epitopes using an EAAAK linker. For the final vaccine construct, four out of six CTL, two out of four HTL and three out of five LBL shortlisted epitopes were chosen based on different combinations and randomization to generate seven potential vaccine candidates, provided in Supplementary Table 5 (see <i>Extended data</i>)<sup><a href="#ref-23">23</a></sup>, and were merged with AAY, GPGPG and KK linkers, respectively (<a href="#f3">Figure 3</a>). The prospective vaccine with the ideal physicochemical property was chosen. The final assembled vaccine is 262 amino acid residues long.</p><a name=f3 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/27552/11a59d69-be6e-4f40-a6ca-41603d4df484_figure3.gif"><img alt="11a59d69-be6e-4f40-a6ca-41603d4df484_figure3.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/27552/11a59d69-be6e-4f40-a6ca-41603d4df484_figure3.gif"></a><div class=caption><h3>Figure 3. Diagram of the assembled vaccine construct outlining 262 amino acids.</h3><p id=d5014e1728> The EAAAK linker was utilized to join the adjuvant at the 5’ end to the rest of the vaccine. CTL epitopes linked with AAY linkers, HTL epitopes linked with GPGPG linkers and form a bridge with the last CTL epitope and first HTL epitope. KK linkers were used to connect LBL epitopes and also form a bridge between the last HTL epitope and the first LBL epitope.</p><p id=d5014e1731>LBL, linear B-lymphocyte; HTL, helper T-lymphocyte; CTL, cytotoxic T-lymphocyte.</p></div></div></div><div class=section><a name=d5014e1740 class=n-a></a><h3 class=section-title>Host-pathogen antigenic similarity</h3><p class="" id=d5014e1745>Evaluation of the multiepitope vaccine protein for similarity against the <i>Homo sapiens</i> proteome was done using BLASTp to ensure safety. No similar proteins were found, which negates the chance of autoimmunity as a result of the vaccine.</p></div><div class=section><a name=d5014e1752 class=n-a></a><h3 class=section-title>Physicochemical properties and solubility</h3><p class="" id=d5014e1757>Physiochemical attributes of the vaccine structure were assessed using the ProtParam tool. The vaccine’s molecular weight was estimated to be ~28 kD and showed good antigenic characteristics. The predicted Isoelectric point (pI) of the designed vaccine is 4.96, indicating an acidic nature, and it has an instability index of 27.79, suggesting that the vaccine will maintain good stability inside the host system. The aliphatic index is 84.73, denoting the thermostable nature of the vaccine. The hydrophilic nature of the vaccine was estimated by the grand average of hydropathicity (GRAVY) score of -0.125. Half-life (t<sub>1/2</sub>) was calculated to be greater than 30 hours in a mammalian reticulocyte, greater than 20 hours in yeast, and more than 10 hours in <i>E. coli</i>. The overall vaccine construct is not allergenic and demonstrated good solubility as shown by the SOLpro server. The above-mentioned assessments suggest that our multiepitope vaccine design has the potential to be a good candidate for RVFV (<a href="#T5">Table 5</a>).</p><a name=T5 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 5. Physicochemical assessments of construct along with antigenic and allergenic properties.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d5014e1780 class=n-a></a><thead><a name=d5014e1782 class=n-a></a><tr><a name=d5014e1784 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d5014e1786 class=n-a></a>Attributes</th><th align=left colspan=1 rowspan=1 valign=top><a name=d5014e1789 class=n-a></a>Value</th></tr></thead><tbody><a name=d5014e1794 class=n-a></a><tr><a name=d5014e1796 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1798 class=n-a></a>Length (amino acids)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1801 class=n-a></a>262</td></tr><tr><a name=d5014e1805 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1807 class=n-a></a>Molecular weight (Dalton)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1810 class=n-a></a>27603.43</td></tr><tr><a name=d5014e1814 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1816 class=n-a></a>Chemical formula</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1819 class=n-a></a>C<sub>1223</sub>H<sub>1964</sub>N<sub>318</sub>O<sub>389</sub>S<sub>8</sub> </td></tr><tr><a name=d5014e1838 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1840 class=n-a></a>Isoelectric point (pI)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1843 class=n-a></a>4.96</td></tr><tr><a name=d5014e1847 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1849 class=n-a></a>Total atoms</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1852 class=n-a></a>3902</td></tr><tr><a name=d5014e1857 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1859 class=n-a></a>Extinction coefficient (at 280 nm in H<sub>2</sub>O)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1865 class=n-a></a>9190 M<sup>-1</sup>cm<sup>-1</sup> </td></tr><tr><a name=d5014e1875 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1877 class=n-a></a>Instability index (II)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1880 class=n-a></a>27.79</td></tr><tr><a name=d5014e1884 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1886 class=n-a></a>Aliphatic index (AI)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1889 class=n-a></a>84.73</td></tr><tr><a name=d5014e1893 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1895 class=n-a></a>Grand average of hydropathicity (GRAVY)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1898 class=n-a></a>-0.125</td></tr><tr><a name=d5014e1902 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1904 class=n-a></a>Solubility</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1907 class=n-a></a>0.826</td></tr><tr><a name=d5014e1911 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1913 class=n-a></a>Antigenicity (VaxiJen v2.0)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1916 class=n-a></a>0.5590 </td></tr><tr><a name=d5014e1921 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1923 class=n-a></a>Allergenicity (AllerTOP v2.0)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d5014e1926 class=n-a></a>Non-allergen</td></tr></tbody></table></div></div><div class=section><a name=d5014e1934 class=n-a></a><h3 class=section-title>Secondary structural features</h3><p class="" id=d5014e1939>The 2D structure of the vaccine design was acquired through the PSIPRED v4.0 workbench. The secondary structure consisted of 49.62% α-helices (130 amino acids), 11.83% β-strands (31 amino acids) and 38.55% random coils (101 amino acids) (<a href="#f4">Figure 4</a>).</p><a name=f4 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/27552/11a59d69-be6e-4f40-a6ca-41603d4df484_figure4.gif"><img alt="11a59d69-be6e-4f40-a6ca-41603d4df484_figure4.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/27552/11a59d69-be6e-4f40-a6ca-41603d4df484_figure4.gif"></a><div class=caption><h3>Figure 4. Secondary structural features of the designed vaccine.</h3><p id=d5014e1955>Herein, α-helix, β-strands, and random coils are represented with pink, yellow and blue colors, respectively.</p></div></div></div><div class=section><a name=d5014e1963 class=n-a></a><h3 class=section-title>Refined 3D structure of the vaccine</h3><p class="" id=d5014e1968>The multiepitope vaccine was speculated and constructed using I-TASSER server. The PDB structure (PDB ID: <a target=xrefwindow href="https://identifiers.org/pdb:1DD4" id=d5014e1970>1DD4</a>) was regarded as the best template for modeling. This server carries out 3D modeling based on the consequence of threading template alignment and simulations are run by merging parameters of the structure assembly. It ranks the confidence of models quantitatively on C-score. The obtained C-score for the modeled 3D vaccine structure was -4.16. The refinement of the 3D structure was carried out by the GalaxyRefine web-tool. The refined and polished model was used to generate a Ramachandran plot, which showed an increased percentage of residues in the favored region. The refined vaccine construct showed 90.0% residues in the favorable region in Ramachandran plot. The global distance test (GDT-HA) score was found to be 0.9055, RMSD was 0.534, MolProbity was 2.209, clash score was 14.2 and poor rotamers were non-existent (<a href="#f5">Figure 5</a>).</p><a name=f5 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/27552/11a59d69-be6e-4f40-a6ca-41603d4df484_figure5.gif"><img alt="11a59d69-be6e-4f40-a6ca-41603d4df484_figure5.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/27552/11a59d69-be6e-4f40-a6ca-41603d4df484_figure5.gif"></a><div class=caption><h3>Figure 5. The tertiary structure of the vaccine where α-helix, β-strand, and random coils are shown in red, yellow, and green, respectively.</h3></div></div></div><div class=section><a name=d5014e1992 class=n-a></a><h3 class=section-title>Validation properties of the 3D vaccine</h3><p class="" id=d5014e1997>The refined tertiary structure was validated using the RAMPAGE server, ProSA-Web tool and Verify3D server. Validation carried out by the RAMPAGE server using a Ramachandran plot of the unrefined 3D structure showed 69.2% of residues in the favorable region, 20.8% in acceptable regions, and 10.0% of the residues in disallowed regions. After structural refinement was carried out, RAMPAGE revealed 90.4% of the vaccine’s residues resided in favorable regions, and 6.2% and 3.5% of residues were found in acceptable and disallowed regions, respectively (<a href="#f6">Figure 6A</a>). The ProSA-web and Verify3D (<a href="#f7">Figure 7</a>) servers were used to validate the unrefined tertiary structure. After refinement, ProSA-web revealed a Z-score of -6.2 for the best vaccine protein model, implying equivalence to the native protein conformation (<a href="#f6">Figure 6B</a>).</p><a name=f6 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/27552/11a59d69-be6e-4f40-a6ca-41603d4df484_figure6.gif"><img alt="11a59d69-be6e-4f40-a6ca-41603d4df484_figure6.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/27552/11a59d69-be6e-4f40-a6ca-41603d4df484_figure6.gif"></a><div class=caption><h3>Figure 6. Qualification of our predicted 3D arrangement of the vaccine.</h3><p id=d5014e2019>(<b>A</b>) Ramachandran plot analysis of the refined model showing favored, allowed and disallowed regions are 90.4%, 6.2% and 3.5%, respectively. (<b>B</b>) Validation using ProSA web tool, revealing a Z-score of -6.2.</p></div></div><a name=f7 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/27552/11a59d69-be6e-4f40-a6ca-41603d4df484_figure7.gif"><img alt="11a59d69-be6e-4f40-a6ca-41603d4df484_figure7.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/27552/11a59d69-be6e-4f40-a6ca-41603d4df484_figure7.gif"></a><div class=caption><h3>Figure 7. Verify3D shows a score of 80.92% for our selected vaccine model.</h3></div></div></div><div class=section><a name=d5014e2047 class=n-a></a><h3 class=section-title>Disulfide bridging in the vaccine structure</h3><p class="" id=d5014e2052>Disulfide bridging was used to stabilize the refined vaccine model. The introduction of cysteine residues was carried out via Disulfide by Design v2.12. Although 23 potential pairs of residues were found (Supplementary Table 7, <i>Extended data</i>)<sup><a href="#ref-23">23</a></sup> suitable for disulfide engineering, only two pairs of residues were chosen based on the energy of binding and χ3 angle. Accordingly, two mutations were created on a pair of selected amino acids, based on the lowest kcal/mol value. For, Leu67-Ala100 residues, the energy value was 2.40 kcal/mol and the χ3 angle was -103.13 degrees and for Phe28-Ala37 duos, the χ3 angle was -111.70 degrees and energy value was 2.86 kcal/mol (<a href="#f8">Figure 8</a>).</p><a name=f8 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/27552/11a59d69-be6e-4f40-a6ca-41603d4df484_figure8.gif"><img alt="11a59d69-be6e-4f40-a6ca-41603d4df484_figure8.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/27552/11a59d69-be6e-4f40-a6ca-41603d4df484_figure8.gif"></a><div class=caption><h3>Figure 8. Disulfide bridging of the vaccine model to increase stability.</h3><p id=d5014e2075> The engineered pairs are indicated by blue and red colors.</p></div></div></div><div class=section><a name=d5014e2084 class=n-a></a><h3 class=section-title>Adapted codons and <i>in silico</i> cloning</h3><p class="" id=d5014e2092>The primary objective is to express our constructed multiepitope vaccine sequence using <i>in silico</i> cloning into the <i>E. coli</i> expression system. As such, the subunit vaccine construct requires codon optimization according to the codon usage for the expression pattern system in <i>E. coli</i>. To optimize for maximal expression of our vaccine design in <i>E. coli</i> K12, the JCat tool was used. The optimized codon sequence was 786 base pairs in length. The GC content was 49.75%, which lies within the ideal range of 30–70%. Codon Adaptation Index was 1.0, which is also within the ideal range (0.8–1.0). This ensures the efficient expression of the multiepitope vaccine inside <i>E. coli</i>. XhoI and BamHI restriction sites were inserted into <i>E. coli</i> plasmid pET28a(+) and the adapted vaccine’s codon sequences were inserted into a recombinant <i>E. coli</i> pET28a(+) plasmid using SnapGene software v5.0.8 (<a href="#f9">Figure 9</a>). The final length of the recombinant construct is 6121 bp.</p><a name=f9 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/27552/11a59d69-be6e-4f40-a6ca-41603d4df484_figure9.gif"><img alt="11a59d69-be6e-4f40-a6ca-41603d4df484_figure9.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/27552/11a59d69-be6e-4f40-a6ca-41603d4df484_figure9.gif"></a><div class=caption><h3>Figure 9. Recombinant plasmid construct pET28a(+) containing multiepitope vaccine was inserted between XhoI (158 bp) and BamHI (950 bp) restriction sites shown in red.</h3><p id=d5014e2130>Outer dark margin represents the vector skeleton.</p></div></div></div><div class=section><a name=d5014e2138 class=n-a></a><h3 class=section-title>Molecular docking studies</h3><p class="" id=d5014e2143>The ClusPro v2.0 server tool was used to conduct molecular docking for characterizing contact between the illustrated refined vaccine and TLR4 (PDB ID: <a target=xrefwindow href="https://identifiers.org/pdb:4G8A" id=d5014e2145>4G8A</a>). This server provided 30 different docked models, the best 10 of which were analyzed for the selection of the appropriate vaccine-receptor complex (Supplementary Table 6, <i>Extended data</i>)<sup><a href="#ref-23">23</a></sup>. The model showing a strong interaction between vaccine residues and the active site of TLR4 along with the lowest energy value was selected. Model 7 fulfilled the above-mentioned criteria, and thus, was picked as the suitable vaccine-receptor complex (<a href="#f10">Figure 10</a>). Model 7 had an energy score of -809.1 and indicated the highest binding affinity as it had the lowest energy score (Supplementary Table 6, <i>Extended data</i>)<sup><a href="#ref-23">23</a></sup>.</p><a name=f10 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/27552/11a59d69-be6e-4f40-a6ca-41603d4df484_figure10.gif"><img alt="11a59d69-be6e-4f40-a6ca-41603d4df484_figure10.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/27552/11a59d69-be6e-4f40-a6ca-41603d4df484_figure10.gif"></a><div class=caption><h3>Figure 10. Interaction between the vaccine and TLR4 receptor.</h3><p id=d5014e2177>Vaccine surface is represented in yellow, while the receptor is represented in cyan.</p></div></div></div><div class=section><a name=d5014e2185 class=n-a></a><h3 class=section-title>Molecular dynamics simulation</h3><p class="" id=d5014e2190>To understand the vaccine-receptor compound stability and its large-scale mobility, NMA was carried out using iMODS tool, which is simulated based on intramural configuration of the whole compound. Deformability of the vaccine-immune receptor complex depends on the isolated movement of every amino acid residue, illustrated via chain hinges (<a href="#f11">Figure 11</a>). The eigenvalue was 2.443455e-5<sup><a href="#ref-57">57</a></sup> (<a href="#f11">Figure 11A</a>). The covariance matrix demonstrates the linkage between duplets of amino acids, the correlated residues marked in red, anti-related residues in white and non-correlated residues in blue, interspersed in dynamical zones (<a href="#f11">Figure 11B</a>). The elastic mesh-work paradigm classifies which pairs of atoms are interlinked by springs and is visualized as a linking matrix. Dots are colored in accordance to their rigidity; the higher the rigidity, the darker the color (<a href="#f11">Figure 11C</a>)<sup><a href="#ref-70">70</a></sup>.</p><a name=f11 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/27552/11a59d69-be6e-4f40-a6ca-41603d4df484_figure11.gif"><img alt="11a59d69-be6e-4f40-a6ca-41603d4df484_figure11.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/27552/11a59d69-be6e-4f40-a6ca-41603d4df484_figure11.gif"></a><div class=caption><h3>Figure 11. </h3><p class=first id=d5014e2221>Molecular dynamic simulation of vaccine-receptor complex, showing (<b>A</b>) eigenvalue; (<b>B</b>) covariance matrix; and (<b>C</b>) elastic network analysis.</p></div></div></div><div class=section><a name=d5014e2238 class=n-a></a><h3 class=section-title>In silico immune responses</h3><p class="" id=d5014e2243>The simulated immune response showed resemblance to an actual immune response against a pathogen (<a href="#f12">Figure 12</a>). Subsequent exposures produced a higher tier immune response compared to the primary immune response. Secondary and tertiary responses showed higher levels of antibodies (i.e., IgM, IgG1, IgG2), which coincides with the waning of antigen (<a href="#f12">Figure 12A</a>). This demonstrates the development of immune memory cells and, as a result, intensified antigen neutralization upon successive exposure (<a href="#f12">Figure 12A</a>). Additionally, several B-lymphocyte cell isotypes with prolonged life have been noticed, signifying potential class switching and memory B cell generation (<a href="#f12">Figure 12B–12C</a>). Increased responses were also observed in helper T cells and cytotoxic T cells with memory generation (<a href="#f12">Figure 12D–12F</a>). An increase in macrophage activity and engagement was perceived, with a vigorous proliferation of dendritic cells (<a href="#f12">Figure 12G–12H</a>). An increased amount of IFN-γ and IL-2 cytokines were also noticed (<a href="#f12">Figure 12l</a>). These findings suggest the development of immune memory and, therefore, immunity against the virus.</p><a name=f12 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/27552/11a59d69-be6e-4f40-a6ca-41603d4df484_figure12.gif"><img alt="11a59d69-be6e-4f40-a6ca-41603d4df484_figure12.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/27552/11a59d69-be6e-4f40-a6ca-41603d4df484_figure12.gif"></a><div class=caption><h3>Figure 12. </h3><p class=first id=d5014e2275><i>In-silico</i> immune response for vaccine construction as an antigen using C-IMMSIM server tool: (<b>A</b>) production of immunoglobulin due to injection of the vaccine; (<b>B</b>) B cell count following consecutive three injections; (<b>C</b>) population of B cell number per state; (<b>D</b>) helper T cell activation; (<b>E</b>) population of helper T cell number per state; (<b>F</b>) population of cytotoxic T cell number per state; (<b>G</b>) per state macrophage population; (<b>H</b>) dendritic cell population; and (<b>I</b>) level of cytokine and interleukins.</p></div></div></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d5014e2316>Discussion</h2><p class="" id=d5014e2319>RVFV causes higher mortality and fatality among animals than in humans. Since this is a zoonotic virus, it can be transmitted through mosquitos and many regions like Africa, the Arabian Peninsula and their neighbors are at risk of an endemic outbreak<sup><a href="#ref-7">7</a></sup>. Thus, a prophylactic measure against RVFV is essential. Vaccination is an ideal approach to gain immunity against infectious agents like RVFV. Development and manufacturing vaccines using a live or attenuated virus takes a huge amount of time and money. Moreover, higher antigenic presence in a weakened vaccine may overstimulate the protective immune system and complicate the situation by causing hypersensitivity reactions<sup><a href="#ref-21">21</a></sup>. In comparison with conventional vaccine strategies, multiepitope vaccines possess no such complications<sup><a href="#ref-71">71</a></sup>. Epitope-based vaccines could be a great choice in terms of safety, viability and economic rationality. In addition, potency as well as immune responses of multiepitope vaccines can be enhanced through the deliberate engineering of targeted epitopes<sup><a href="#ref-72">72</a></sup>. Researchers have been looking for a way to reduce the budget for vaccine development, as well as minimizing allergenicity and side-effects of vaccines for quite a long time. With the emergence of new computational technology and widely available databases, different strategies are now available for designing and developing epitope-based vaccines following immunoinformatics expedients<sup><a href="#ref-73">73</a>,<a href="#ref-74">74</a></sup>. Vaccines against multitudes of viruses such as SARS-CoV-2, Ebola, Lassa, hepatitis C, Oropouche, Dengue and many more in the pipeline are prime examples of a structural vaccinology approach applied to the design of a multiepitope vaccine model<sup><a href="#ref-17">17</a>,<a href="#ref-19">19</a>,<a href="#ref-75">75</a>–<a href="#ref-79">79</a></sup>. In this study, our primary focus was to devise a multiepitope vaccine with the ability to produce robust immunity against RVFV having considered all the parameters of a subunit vaccine.</p><p class="" id=d5014e2359>After retrieving the 232 complete proteomes of RVFV from the ViPR server, screening for antigenic proteins was executed and glycoprotein sequences were selected based on higher antigenicity. A potent multiepitope vaccine should possess the potential to trigger B and T cell activation<sup><a href="#ref-71">71</a></sup>. Therefore, potential CTL, HTL as well as LBL epitopic regions of RVFV glycoprotein were chosen for a candidate vaccine modeling. We were particularly interested in integrating B cell epitopes due to its function in antibody production and memory cell formation<sup><a href="#ref-80">80</a></sup>. T cell-mediated immunity was also a concern in our vaccine design since plasma cells that give rise to humoral response reactions can easily be saturated by the deluge of antigens. Moreover, lifelong resistance can also be achieved by cell-mediated immunity or cytotoxic T cells<sup><a href="#ref-81">81</a></sup>. Cytotoxic T cells can provide lifelong immunity through identifying and destroying infected cells<sup><a href="#ref-82">82</a></sup>. Helper T cells, on the other hand, stimulate the release of IL-10, IL-4 and IFN-γ to overcome pro-inflammatory responses and lessen the damage caused to tissues and cells. Besides, they help to produce IgG antibodies and neutralize RVFV infection from peripheral system<sup><a href="#ref-83">83</a></sup>. Furthermore, CD4+ cell activate B cells, macrophages, CD8+ cells when they come into contact with an antigen. Thus, all these points were considered and examined during our pursuit of designing the RVFV vaccine.</p><p class="" id=d5014e2382>In a previous study, Adhikari and Rahman predicted overlapping immunodominant T cell epitopes from both nucleocapsid and glycoprotein<sup><a href="#ref-84">84</a></sup>. However, their study concluded without formulating the vaccine candidate. Therefore, while Adhikari and Rahman focused on finding overlapping conserved CD8+ and CD4+ epitopes, our work was more centered on selecting CD8+ and CD4+ epitopes with high antigenicity, immunogenicity, non-allergenicity, non-toxicity and eventually tailoring them into a rational and potent vaccine candidate. Herein, unique epitopes from helper and cytotoxic T cells and B cells were chosen not only based on their antigenicity but also on other factors including allergenicity, immunogenicity and toxicity. The complete vaccine design was assembled by attaching the chosen CTL, followed by HTL and finally B cell peptides with the help of AAY, GPGPG, and KK linkers, respectively. Linkers were incorporated in vaccine construction as a part of an essential element to enhance stability, folding, and expression patterns of our vaccine protein<sup><a href="#ref-85">85</a></sup>. The adjuvant L7/L12 ribosomal protein was attached to the first CTL epitope using the linker EAAAK. Multiepitope vaccines are less immunogenic when used alone due to a reduction in molecular weight compared to the protein, hence, it requires adjuvant to enhance its efficiency<sup><a href="#ref-86">86</a></sup>. Adjuvants are components that help heighten cellular and humoral immunogenic responses for particular antigens as well as amplify the vaccine’s stability and longevity<sup><a href="#ref-87">87</a>,<a href="#ref-88">88</a></sup>.</p><p class="" id=d5014e2404>Due to the inclusion of immune dominant epitopes, the vaccine candidate was found to have higher antigenicity and immunogenicity while being devoid of allergenic feature. These are the prime features for a vaccine to be effective immune modulator in the first place. When it comes to peptide or subunit vaccines, the size of the vaccine candidate becomes an important matter. Interestingly, our designed multiepitope vaccine is only ~28 kD in size which makes it a suitable candidate vaccine. Solubility is another vital characteristic for any recombinant vaccine<sup><a href="#ref-16">16</a></sup>. Luckily, our vaccine construct was predicted to be highly soluble inside the host <i>E. coli</i> system. Furthermore, physicochemical properties of the vaccine candidate were also in suitable range. For instance, the instability index suggested that the chimeric protein would remain stable after synthesis, while the GRAVY value and aliphatic index portrayed the vaccine to be hydrophilic and thermostable, respectively. However, the theoretical pI anticipated our vaccine as acidic which can be adjusted by modifying or adding some basic linkers or additional adjuvants.</p><p class="" id=d5014e2415>The arrangement of crucial protein components was determined by 3D structure modeling, which was used for studying protein dynamics, functions, networking between residues and ligand interactions. The vaccine candidate that showed the best physio-chemical property was chosen and the vaccine construct was refined to significantly improve its expedient properties. The Ramachandran plot revealed 96.6% residues resided within the combined favored and acceptable regions along with only a couple of residues in disallowed region, which confirms the merit of the model. The GDT-HA and MolProbity score, along with clashscore, RMSD value and poor rotamer values were also indicative of sufficiency of the designed vaccine. The Z-score (-6.2) and Verify3D score (80.92%) also signal the satisfactory quality of the vaccine.</p><p class="" id=d5014e2418>Molecular docking as well as molecular dynamics simulation of the TLR4 and vaccine complex were performed in order to gain knowledge about the binding strength, contact nature and structural integrity. The vaccine-receptor complex underwent energy minimization, resulting in boosting of the stability of the total combination. The eigenvalue suggests the stiffness of motion of the molecules within the system and energy needed for their distortion. In our study, eigenvalue increases with each mode passed by which indicates more rigid and compact structure given the time.</p><p class="" id=d5014e2421>Serological evaluation to verify immuno-reactivity can be carried out for validating the candidate vaccine<sup><a href="#ref-89">89</a></sup>. Thus, observation of the designed vaccine protein’s expression inside a suitable host is necessary. <i>E. coli</i> has been considered to be a great host choice for determining a recombinant protein’s expression patterns<sup><a href="#ref-90">90</a>,<a href="#ref-91">91</a></sup>. Hence, codon adaptation was accomplished for our recombinant vaccine to generate high levels of protein expression in <i>E. coli</i> K12. A CAI value of 1.0 and 49.75% GC content suggests the capability of optimum protein synthesis in the host. Moreover, two disulfide bridges were engineered into the vaccine for better stabilization, which is paramount for various biological and biotechnological applications. Animals immunized with glycoproteins of RVFV have been seen to produce protective antibodies against RVFV. Schmaljohn <i>et al.</i> have stated that mice inoculated with Sf9 cells expressing G1 and G2 glycoproteins of RVFV have produced antibodies that are adaptive in nature and neutralizes RVFV infection<sup><a href="#ref-92">92</a></sup>. In a study conducted by Faburay <i>et al.</i> construction of a peptide vaccine consisting of two glycoprotein subunits Gn and Gc was carried out against RVFV, and injected into sheep to determine its neutralizing effects. Six sheep were immunized with their constructed subunit vaccine with a dose of 50 μg. The vaccine elicited a strong antibody response against RVFV which was confirmed using enzyme-linked immunosorbent assay (ELISA), suggesting recombinant glycoproteins can be used as a good subunit vaccine candidate. Faburay and his team further carried out a plaque reduction neutralization test to check the amount antibodies produced on primary and secondary dosages. Titer of first dose was low, but the second dosage increased the titer over 1280<sup><a href="#ref-14">14</a></sup>.</p><p class="" id=d5014e2456>In current study, we also carried out the immune simulation of the vaccine candidate in an <i>in silico</i> immune simulator which demonstrated a good pattern of immune responses<i>.</i> As repetitive vaccine doses enhanced immune responses, we administered three doses that produced a variety of B-cell isotypes and T cell-mediated immune reactions with a noticeably significant number of memory B cells having a half-life of several months. Our simulated immune response shows a stronger and active immune response on secondary and tertiary doses, compared to the initial primary dose. IgG and IgM antibodies had an arbitrary titer of 80000 on second dose and 120000 on third dose. Sustained generation of IFN-γ and IL-2 was observed after multiple exposures of the vaccine as a result of increased helper T cell activation and therefore, the vaccine effectively stimulated a humoral immune response to ramp up immunoglobulin production.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d5014e2469>Conclusion</h2><p class="" id=d5014e2472>RVFV is a pathogenic agent with potential to become more widespread in upcoming times. Multiepitope vaccines provide a modular and tunable approach to vaccine design compared to traditional vaccine efforts. Our study focused on designing an effective and potent multiepitope vaccine to provide immunity against RVFV. The vaccine contained <i>in silico</i> assessed and predicted CTL, HTL, and LBL epitopes to produce an effective cellular and humoral immunologic response. Moreover, the vaccine simulation showed a potentially protective immune response and passed all molecular simulations with favorable results. However, further validation is required in <i>in vivo</i> and <i>in vitro</i> systems to guarantee the effectiveness of our designed vaccine.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d5014e2487>Data availability</h2><div class=section><a name=d5014e2490 class=n-a></a><h3 class=section-title>Underlying data</h3><p class="" id=d5014e2495>All data underlying the results are available as part of the article and no additional source data are required.</p></div><div class=section><a name=d5014e2499 class=n-a></a><h3 class=section-title>Extended data</h3><p class="" id=d5014e2504>Harvard Dataverse: Extended DATA: Discovery of potential immune epitopes and peptide vaccine design - a prophylactic strategy against Rift Valley Fever Virus. <a target=xrefwindow href="https://doi.org/10.7910/DVN/B9Y1EH" id=d5014e2506>https://doi.org/10.7910/DVN/B9Y1EH</a><sup><a href="#ref-23">23</a></sup>.</p><p class="" id=d5014e2513>This project contains the following extended data in DOCX format:<div class=list><a name=d5014e2515 class=n-a></a><ul style="list-style-type: none"><li><p id=d5014e2522><span class=label>- </span> Supplementary Table 1 (All initially retrieved complete RVFV protein sequences)</p></li><li><p id=d5014e2531><span class=label>- </span> Supplementary Table 2 (Predicted all potential cytotoxic T-lymphocyte epitopes)</p></li><li><p id=d5014e2540><span class=label>- </span> Supplementary Table 3 (Predicted all potential helper T-lymphocyte epitopes)</p></li><li><p id=d5014e2549><span class=label>- </span> Supplementary Table 4 (Predicted all potential linear B-lymphocyte epitopes)</p></li><li><p id=d5014e2558><span class=label>- </span> Supplementary Table 5 (Physicochemical properties of all designed vaccine candidates)</p></li><li><p id=d5014e2568><span class=label>- </span> Supplementary Table 6 (Scores of top-10 best vaccine-TLR4 docked complexes)</p></li><li><p id=d5014e2577><span class=label>- </span> Supplementary Table 7 (Potential residue pairs for disulfide bridging)</p></li></ul></div> </p><p class="" id=d5014e2583>Data are available under the terms of the <a target=xrefwindow href="https://creativecommons.org/publicdomain/zero/1.0/" id=d5014e2585>Creative Commons Zero “No rights reserved” data waiver</a> (CC0 1.0 Public domain dedication).</p></div><div class=section><a name=d5014e2590 class=n-a></a><h3 class=section-title>Author endorsement</h3><p class="" id=d5014e2595>Mohammad Minnatul Karim confirms that the author has an appropriate level of expertise to conduct this research, and confirms that the submission is of an acceptable scientific standard. Mohammad Minnatul Karim declares they have no competing interests. Affiliation: Department of Biotechnology and Genetic Engineering, Islamic University, Bangladesh.</p></div></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d5014e2603 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading is-hidden"><span class=faculty-opinion-icon></span><span class="prime-red big">Faculty Opinions recommended</span></span><h2 class=main-title id=d5720>References</h2><div class="section ref-list"><a name=d5014e2603 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d5014e2610 class=n-a></a>Davies FG, Linthicum KJ, James AD: Rainfall and epizootic Rift Valley fever. <i>Bull World Health Organ.</i> 1985; <b>63</b>(5): 941–3. <a target=xrefwindow id=d5014e2618 href="http://www.ncbi.nlm.nih.gov/pubmed/3879206">PubMed Abstract </a> | <a target=xrefwindow id=d5014e2621 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2536443">Free Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d5014e2630 class=n-a></a>Bird BH, Ksiazek TG, Nichol ST, <i> et al.</i>: Rift Valley fever virus. <i>J Am Vet Med Assoc.</i> 2009; <b>234</b>(7): 883–93. <a target=xrefwindow id=d5014e2641 href="http://www.ncbi.nlm.nih.gov/pubmed/19335238">PubMed Abstract </a> | <a target=xrefwindow id=d5014e2644 href="https://doi.org/10.2460/javma.234.7.883">Publisher Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d5014e2653 class=n-a></a>Bouloy M, Weber F: Molecular Biology of Rift Valley Fever Virus. <i>Open Virol J.</i> 2010; <b>4</b>(1): 8–14. <a target=xrefwindow id=d5014e2661 href="http://www.ncbi.nlm.nih.gov/pubmed/20517489">PubMed Abstract </a> | <a target=xrefwindow id=d5014e2664 href="https://doi.org/10.2174/1874357901004020008">Publisher Full Text </a> | <a target=xrefwindow id=d5014e2667 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2878978">Free Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d5014e2676 class=n-a></a>Daubney R, Hudson JR, Garnham PC: Enzootic hepatitis or rift valley fever. An undescribed virus disease of sheep cattle and man from east africa. <i>J Pathol Bacteriol.</i> 1931; <b>34</b>(4): 545–79. <a target=xrefwindow id=d5014e2684 href="https://doi.org/10.1002/path.1700340418">Publisher Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d5014e2693 class=n-a></a>Ikegami T, Makino S: The Pathogenesis of Rift Valley Fever. <i>Viruses.</i> 2011; <b>3</b>(5): 493–519. <a target=xrefwindow id=d5014e2701 href="http://www.ncbi.nlm.nih.gov/pubmed/21666766">PubMed Abstract </a> | <a target=xrefwindow id=d5014e2704 href="https://doi.org/10.3390/v3050493">Publisher Full Text </a> | <a target=xrefwindow id=d5014e2707 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3111045">Free Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d5014e2717 class=n-a></a>Coetzer JAW, Thomson GR, Tustin RC: Infectious diseases of livestock with special reference to Southern Africa. Cape Town; New York: Oxford University Press; 1994. <a target=xrefwindow id=d5014e2719 href="https://books.google.co.in/books/about/Infectious_Diseases_of_Livestock.html?id=3GRWAAAAYAAJ&amp;redir_esc=y">Reference Source</a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d5014e2728 class=n-a></a>LaBeaud AD, Muchiri EM, Ndzovu M, <i> et al.</i>: Interepidemic Rift Valley Fever Virus Seropositivity, Northeastern Kenya. <i>Emerg Infect Dis.</i> 2008; <b>14</b>(8): 1240–6. <a target=xrefwindow id=d5014e2739 href="http://www.ncbi.nlm.nih.gov/pubmed/18680647">PubMed Abstract </a> | <a target=xrefwindow id=d5014e2742 href="https://doi.org/ 10.3201/eid1408.080082">Publisher Full Text </a> | <a target=xrefwindow id=d5014e2746 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2600406">Free Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d5014e2755 class=n-a></a>Antonis Afg, Kortekaas J, Kant J, <i> et al.</i>: Vertical Transmission of Rift Valley Fever Virus Without Detectable Maternal Viremia. <i>Vector-Borne Zoonotic Dis.</i> 2013; <b>13</b>(8): 601–6. <a target=xrefwindow id=d5014e2766 href="http://www.ncbi.nlm.nih.gov/pubmed/23682700">PubMed Abstract </a> | <a target=xrefwindow id=d5014e2769 href="https://doi.org/10.1089/vbz.2012.1160">Publisher Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d5014e2778 class=n-a></a>Hartman A: Rift Valley Fever. <i>Clin Lab Med.</i> 2017; <b>37</b>(2): 285–301. <a target=xrefwindow id=d5014e2786 href="http://www.ncbi.nlm.nih.gov/pubmed/28457351">PubMed Abstract </a> | <a target=xrefwindow id=d5014e2789 href="https://doi.org/10.1016/j.cll.2017.01.004">Publisher Full Text </a> | <a target=xrefwindow id=d5014e2792 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5458783">Free Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d5014e2801 class=n-a></a>Tigoi C, Sang R, Chepkorir E, <i> et al.</i>: High risk for human exposure to Rift Valley fever virus in communities living along livestock movement routes: A cross-sectional survey in Kenya. <i>PLoS Negl Trop Dis.</i> 2020; <b>14</b>(2): e0007979. <a target=xrefwindow id=d5014e2812 href="http://www.ncbi.nlm.nih.gov/pubmed/32084127">PubMed Abstract </a> | <a target=xrefwindow id=d5014e2815 href="https://doi.org/ 10.1371/journal.pntd.0007979">Publisher Full Text </a> | <a target=xrefwindow id=d5014e2819 href="http://www.ncbi.nlm.nih.gov/pmc/articles/7055907">Free Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d5014e2828 class=n-a></a>Anyangu AS, Gould LH, Sharif SK, <i> et al.</i>: Risk Factors for Severe Rift Valley Fever Infection in Kenya, 2007. <i>Am J Trop Med Hyg.</i> 2010; <b>83</b>(2 Suppl): 14–21. <a target=xrefwindow id=d5014e2839 href="http://www.ncbi.nlm.nih.gov/pubmed/20682901">PubMed Abstract </a> | <a target=xrefwindow id=d5014e2842 href="https://doi.org/10.4269/ajtmh.2010.09-0293">Publisher Full Text </a> | <a target=xrefwindow id=d5014e2846 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2913492">Free Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d5014e2856 class=n-a></a>Gerrard SR, Bird BH, Albariño CG, <i> et al.</i>: The NSm proteins of Rift Valley fever virus are dispensable for maturation, replication and infection. <i>Virology.</i> 2007; <b>359</b>(2): 459–65. <a target=xrefwindow id=d5014e2867 href="http://www.ncbi.nlm.nih.gov/pubmed/17070883">PubMed Abstract </a> | <a target=xrefwindow id=d5014e2870 href="https://doi.org/10.1016/j.virol.2006.09.035">Publisher Full Text </a> | <a target=xrefwindow id=d5014e2874 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2364454">Free Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d5014e2883 class=n-a></a>Besselaar TG, Blackburn NK: The effect of neutralizing monoclonal antibodies on early events in Rift Valley fever virus infectivity. <i>Res Virol.</i> 1994; <b>145</b>(1): 13–9. <a target=xrefwindow id=d5014e2891 href="http://www.ncbi.nlm.nih.gov/pubmed/7517569">PubMed Abstract </a> | <a target=xrefwindow id=d5014e2894 href="https://doi.org/10.1016/s0923-2516(07)80002-1">Publisher Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d5014e2903 class=n-a></a>Faburay B, Lebedev M, McVey DS, <i> et al.</i>: A Glycoprotein Subunit Vaccine Elicits a Strong Rift Valley Fever Virus Neutralizing Antibody Response in Sheep. <i>Vector Borne Zoonotic Dis.</i> 2014; <b>14</b>(10): 746–56. <a target=xrefwindow id=d5014e2914 href="http://www.ncbi.nlm.nih.gov/pubmed/25325319">PubMed Abstract </a> | <a target=xrefwindow id=d5014e2917 href="https://doi.org/10.1089/vbz.2014.1650">Publisher Full Text </a> | <a target=xrefwindow id=d5014e2921 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4208602">Free Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d5014e2930 class=n-a></a>Nezafat N, Eslami M, Negahdaripour M, <i> et al.</i>: Designing an efficient multi-epitope oral vaccine against Helicobacter pylori using immunoinformatics and structural vaccinology approaches. <i>Mol Biosyst.</i> 2017; <b>13</b>(4): 699–713. <a target=xrefwindow id=d5014e2941 href="http://www.ncbi.nlm.nih.gov/pubmed/28194462">PubMed Abstract </a> | <a target=xrefwindow id=d5014e2944 href="https://doi.org/10.1039/c6mb00772d">Publisher Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d5014e2953 class=n-a></a>Khatoon N, Pandey RK, Prajapati VK: Exploring <i>Leishmania</i> secretory proteins to design B and T cell multi-epitope subunit vaccine using immunoinformatics approach. <i>Sci Rep.</i> 2017; <b>7</b>(1): 8285. <a target=xrefwindow id=d5014e2964 href="http://www.ncbi.nlm.nih.gov/pubmed/28811600">PubMed Abstract </a> | <a target=xrefwindow id=d5014e2967 href="https://doi.org/10.1038/s41598-017-08842-w">Publisher Full Text </a> | <a target=xrefwindow id=d5014e2971 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5557753">Free Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d5014e2980 class=n-a></a>Samad A, Ahammad F, Nain Z, <i> et al.</i>: Designing a multi-epitope vaccine against SARS-CoV-2: an immunoinformatics approach. <i>J Biomol Struct Dyn.</i> 2020; 1–17. <a target=xrefwindow id=d5014e2988 href="http://www.ncbi.nlm.nih.gov/pubmed/32677533">PubMed Abstract </a> | <a target=xrefwindow id=d5014e2991 href="https://doi.org/10.1080/07391102.2020.1792347">Publisher Full Text </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d5014e3001 class=n-a></a>Nain Z, Karim MM, Sen MK, <i> et al.</i>: Structural basis and designing of peptide vaccine using PE-PGRS family protein of <i>Mycobacterium ulcerans</i>-An integrated vaccinomics approach. <i>Mol Immunol.</i> 2020; <b>120</b>: 146–63. <a target=xrefwindow id=d5014e3015 href="http://www.ncbi.nlm.nih.gov/pubmed/32126449">PubMed Abstract </a> | <a target=xrefwindow id=d5014e3019 href="https://doi.org/10.1016/j.molimm.2020.02.009">Publisher Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d5014e3028 class=n-a></a>Sayed SB, Nain Z, Khan MdSA, <i> et al.</i>: Exploring Lassa Virus Proteome to Design a Multi-epitope Vaccine Through Immunoinformatics and Immune Simulation Analyses. <i>Int J Pept Res Ther.</i> 2020; 1–19. <a target=xrefwindow id=d5014e3036 href="http://www.ncbi.nlm.nih.gov/pubmed/32421065">PubMed Abstract </a> | <a target=xrefwindow id=d5014e3039 href="https://doi.org/10.1007/s10989-019-10003-8">Publisher Full Text </a> | <a target=xrefwindow id=d5014e3042 href="http://www.ncbi.nlm.nih.gov/pmc/articles/7223894">Free Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d5014e3051 class=n-a></a>Nain Z, Abdulla F, Rahman MM, <i> et al.</i>: Proteome-wide screening for designing a multi-epitope vaccine against emerging pathogen <i>Elizabethkingia anophelis</i> using immunoinformatic approaches. <i>J Biomol Struct Dyn.</i> 2019; 1–18. <a target=xrefwindow id=d5014e3062 href="http://www.ncbi.nlm.nih.gov/pubmed/31709929">PubMed Abstract </a> | <a target=xrefwindow id=d5014e3065 href="https://doi.org/10.1080/07391102.2019.1692072">Publisher Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d5014e3074 class=n-a></a>Li W, Joshi MD, Singhania S, <i> et al.</i>: Peptide Vaccine: Progress and Challenges. <i>Vaccines (Basel).</i> 2014; <b>2</b>(3): 515–36. <a target=xrefwindow id=d5014e3085 href="http://www.ncbi.nlm.nih.gov/pubmed/26344743">PubMed Abstract </a> | <a target=xrefwindow id=d5014e3088 href="https://doi.org/10.3390/vaccines2030515">Publisher Full Text </a> | <a target=xrefwindow id=d5014e3092 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4494216">Free Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d5014e3101 class=n-a></a>Gaafar BBM, Ali SA, Abd-elrahman KA, <i> et al.</i>: Immunoinformatics Approach for Multiepitope Vaccine Prediction from H, M, F, and N Proteins of Peste des Petits Ruminants Virus. <i>J Immunol Res.</i> Hindawi; 2019; <b>2019</b>: e6124030. <a target=xrefwindow id=d5014e3112 href="http://www.ncbi.nlm.nih.gov/pubmed/31781679">PubMed Abstract </a> | <a target=xrefwindow id=d5014e3115 href="https://doi.org/ 10.1155/2019/6124030">Publisher Full Text </a> | <a target=xrefwindow id=d5014e3119 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6875335">Free Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d5014e3128 class=n-a></a>Nain Z, Bhuiyan MA, Quayum ST, <i> et al.</i>: "Extended DATA: Discovery of Potential Immune Epitopes and Peptide Vaccine Design - A Prophylactic Strategy against Rift Valley Fever Virus". <i>Harvard Dataverse, V2.</i> 2020. <a target=xrefwindow id=d5014e3136 href="http://www.doi.org/10.7910/DVN/B9Y1EH">http://www.doi.org/10.7910/DVN/B9Y1EH</a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d5014e3146 class=n-a></a>Pickett BE, Sadat EL, Zhang Y, <i> et al.</i>: ViPR: an open bioinformatics database and analysis resource for virology research. <i>Nucleic Acids Res.</i> 2012; <b>40</b>(Database issue): D593–8. <a target=xrefwindow id=d5014e3157 href="http://www.ncbi.nlm.nih.gov/pubmed/22006842">PubMed Abstract </a> | <a target=xrefwindow id=d5014e3160 href="https://doi.org/10.1093/nar/gkr859">Publisher Full Text </a> | <a target=xrefwindow id=d5014e3164 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3245011">Free Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d5014e3173 class=n-a></a>Doytchinova IA, Flower DR: VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines. <i>BMC Bioinformatics.</i> 2007; <b>8</b>(1): 4. <a target=xrefwindow id=d5014e3181 href="http://www.ncbi.nlm.nih.gov/pubmed/17207271">PubMed Abstract </a> | <a target=xrefwindow id=d5014e3184 href="https://doi.org/10.1186/1471-2105-8-4">Publisher Full Text </a> | <a target=xrefwindow id=d5014e3187 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1780059">Free Full Text </a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d5014e3196 class=n-a></a>Larsen MV, Lundegaard C, Lamberth K, <i> et al.</i>: Large-scale validation of methods for cytotoxic T-lymphocyte epitope prediction. <i>BMC Bioinformatics.</i> 2007; <b>8</b>(1): 424. <a target=xrefwindow id=d5014e3207 href="http://www.ncbi.nlm.nih.gov/pubmed/17973982">PubMed Abstract </a> | <a target=xrefwindow id=d5014e3210 href="https://doi.org/10.1186/1471-2105-8-424">Publisher Full Text </a> | <a target=xrefwindow id=d5014e3214 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2194739">Free Full Text </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d5014e3223 class=n-a></a>Moutaftsi M, Peters B, Pasquetto V, <i> et al.</i>: A consensus epitope prediction approach identifies the breadth of murine T(CD8+)-cell responses to vaccinia virus. <i>Nat Biotechnol.</i> 2006; <b>24</b>(7): 817–9. <a target=xrefwindow id=d5014e3234 href="http://www.ncbi.nlm.nih.gov/pubmed/16767078">PubMed Abstract </a> | <a target=xrefwindow id=d5014e3237 href="https://doi.org/10.1038/nbt1215">Publisher Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d5014e3246 class=n-a></a>Calis JJA, Maybeno M, Greenbaum JA, <i> et al.</i>: Properties of MHC Class I Presented Peptides That Enhance Immunogenicity. <i>PLoS Comput Biol.</i> 2013; <b>9</b>(10): e1003266. <a target=xrefwindow id=d5014e3257 href="http://www.ncbi.nlm.nih.gov/pubmed/24204222">PubMed Abstract </a> | <a target=xrefwindow id=d5014e3260 href="https://doi.org/10.1371/journal.pcbi.1003266">Publisher Full Text </a> | <a target=xrefwindow id=d5014e3264 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3808449">Free Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d5014e3273 class=n-a></a>Dimitrov I, Bangov IP, Flower DR, <i> et al.</i>: AllerTOP v.2—a server for <i>in silico</i> prediction of allergens. <i>J Mol Model.</i> 2014; <b>20</b>(6): 2278. <a target=xrefwindow id=d5014e3287 href="http://www.ncbi.nlm.nih.gov/pubmed/24878803">PubMed Abstract </a> | <a target=xrefwindow id=d5014e3291 href="https://doi.org/10.1007/s00894-014-2278-5">Publisher Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d5014e3301 class=n-a></a>Gupta S, Kapoor P, Chaudhary K, <i> et al.</i>: <i>In Silico</i> Approach for Predicting Toxicity of Peptides and Proteins. <i>PLoS One.</i> 2013; <b>8</b>(9): e73957. <a target=xrefwindow id=d5014e3315 href="http://www.ncbi.nlm.nih.gov/pubmed/24058508">PubMed Abstract </a> | <a target=xrefwindow id=d5014e3319 href="https://doi.org/ 10.1371/journal.pone.0073957">Publisher Full Text </a> | <a target=xrefwindow id=d5014e3322 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3772798">Free Full Text </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d5014e3331 class=n-a></a>Alexander J, Fikes J, Hoffman S, <i> et al.</i>: The optimization of helper T lymphocyte (HTL) function in vaccine development. <i>Immunol Res.</i> 1998; <b>18</b>(2): 79–92. <a target=xrefwindow id=d5014e3342 href="http://www.ncbi.nlm.nih.gov/pubmed/9844827">PubMed Abstract </a> | <a target=xrefwindow id=d5014e3345 href="https://doi.org/10.1007/BF02788751">Publisher Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d5014e3354 class=n-a></a>Wang P, Sidney J, Dow C, <i> et al.</i>: A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach. <i>PLoS Comput Biol.</i> 2008; <b>4</b>(4): e1000048. <a target=xrefwindow id=d5014e3365 href="http://www.ncbi.nlm.nih.gov/pubmed/18389056">PubMed Abstract </a> | <a target=xrefwindow id=d5014e3368 href="https://doi.org/10.1371/journal.pcbi.1000048">Publisher Full Text </a> | <a target=xrefwindow id=d5014e3372 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2267221">Free Full Text </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d5014e3381 class=n-a></a>Dhanda SK, Vir P, Raghava GP: Designing of interferon-gamma inducing MHC class-II binders. <i>Biol Direct.</i> 2013; <b>8</b>(1): 30. <a target=xrefwindow id=d5014e3389 href="http://www.ncbi.nlm.nih.gov/pubmed/24304645">PubMed Abstract </a> | <a target=xrefwindow id=d5014e3392 href="https://doi.org/10.1186/1745-6150-8-30">Publisher Full Text </a> | <a target=xrefwindow id=d5014e3395 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4235049">Free Full Text </a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d5014e3404 class=n-a></a>Dhanda SK, Gupta S, Vir P, <i> et al.</i>: Prediction of IL4 Inducing Peptides. <i>Clin Dev Immunol.</i> Hindawi; 2013; <b>2013</b>: e263952. <a target=xrefwindow id=d5014e3415 href="http://www.ncbi.nlm.nih.gov/pubmed/24489573">PubMed Abstract </a> | <a target=xrefwindow id=d5014e3418 href="https://doi.org/10.1155/2013/263952">Publisher Full Text </a> | <a target=xrefwindow id=d5014e3422 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3893860">Free Full Text </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d5014e3431 class=n-a></a>Nagpal G, Usmani SS, Dhanda SK, <i> et al.</i>: Computer-aided designing of immunosuppressive peptides based on IL-10 inducing potential. <i>Sci Rep.</i> 2017; <b>7</b>(1): 42851. <a target=xrefwindow id=d5014e3442 href="http://www.ncbi.nlm.nih.gov/pubmed/28211521">PubMed Abstract </a> | <a target=xrefwindow id=d5014e3445 href="https://doi.org/10.1038/srep42851">Publisher Full Text </a> | <a target=xrefwindow id=d5014e3449 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5314457">Free Full Text </a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d5014e3459 class=n-a></a>Manavalan B, Govindaraj RG, Shin TH, <i> et al.</i>: iBCE-EL: A New Ensemble Learning Framework for Improved Linear B-Cell Epitope Prediction. <i>Front Immunol.</i> 2018; <b>9</b>: 1695. <a target=xrefwindow id=d5014e3470 href="http://www.ncbi.nlm.nih.gov/pubmed/30100904">PubMed Abstract </a> | <a target=xrefwindow id=d5014e3473 href="https://doi.org/10.3389/fimmu.2018.01695">Publisher Full Text </a> | <a target=xrefwindow id=d5014e3477 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6072840">Free Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d5014e3486 class=n-a></a>González-Galarza FF, Takeshita LYC, Santos EJM, <i> et al.</i>: Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations. <i>Nucleic Acids Res.</i> 2015; <b>43</b>(Database issue): D784–8. <a target=xrefwindow id=d5014e3497 href="http://www.ncbi.nlm.nih.gov/pubmed/25414323">PubMed Abstract </a> | <a target=xrefwindow id=d5014e3500 href="https://doi.org/10.1093/nar/gku1166">Publisher Full Text </a> | <a target=xrefwindow id=d5014e3504 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4383964">Free Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d5014e3513 class=n-a></a>Bui HH, Sidney J, Dinh K, <i> et al.</i>: Predicting population coverage of T-cell epitope-based diagnostics and vaccines. <i>BMC Bioinformatics.</i> 2006; <b>7</b>: 153. <a target=xrefwindow id=d5014e3524 href="http://www.ncbi.nlm.nih.gov/pubmed/16545123">PubMed Abstract </a> | <a target=xrefwindow id=d5014e3527 href="https://doi.org/10.1186/1471-2105-7-153">Publisher Full Text </a> | <a target=xrefwindow id=d5014e3531 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1513259">Free Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d5014e3540 class=n-a></a>Olejnik J, Hume AJ, Mühlberger E: Toll-like receptor 4 in acute viral infection: Too much of a good thing. <i>PLoS Pathog.</i> 2018; <b>14</b>(12): e1007390. <a target=xrefwindow id=d5014e3548 href="http://www.ncbi.nlm.nih.gov/pubmed/30571771">PubMed Abstract </a> | <a target=xrefwindow id=d5014e3551 href="https://doi.org/10.1371/journal.ppat.1007390">Publisher Full Text </a> | <a target=xrefwindow id=d5014e3554 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6301565">Free Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d5014e3563 class=n-a></a>Pandey RK, Bhatt TK, Prajapati VK: Novel Immunoinformatics Approaches to Design Multi-epitope Subunit Vaccine for Malaria by Investigating <i>Anopheles</i> Salivary Protein. <i>Sci Rep.</i> 2018; <b>8</b>(1): 1125. <a target=xrefwindow id=d5014e3574 href="http://www.ncbi.nlm.nih.gov/pubmed/29348555">PubMed Abstract </a> | <a target=xrefwindow id=d5014e3577 href="https://doi.org/10.1038/s41598-018-19456-1">Publisher Full Text </a> | <a target=xrefwindow id=d5014e3581 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5773588">Free Full Text </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d5014e3590 class=n-a></a>Wei XH, Wei X, Chen FY, <i> et al.</i>: The Upregulation of Translocator Protein (18 kDa) Promotes Recovery from Neuropathic Pain in Rats. <i>J Neurosci.</i> 2013; <b>33</b>(4): 1540–51. <a target=xrefwindow id=d5014e3601 href="http://www.ncbi.nlm.nih.gov/pubmed/23345228">PubMed Abstract </a> | <a target=xrefwindow id=d5014e3604 href="https://doi.org/10.1523/JNEUROSCI.0324-12.2013">Publisher Full Text </a> | <a target=xrefwindow id=d5014e3608 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6618728">Free Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d5014e3618 class=n-a></a>Arai R, Ueda H, Kitayama A, <i> et al.</i>: Design of the linkers which effectively separate domains of a bifunctional fusion protein. <i>Protein Eng Des Sel.</i> 2001; <b>14</b>(8): 529–32. <a target=xrefwindow id=d5014e3629 href="https://doi.org/10.1093/protein/14.8.529">Publisher Full Text </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a name=d5014e3638 class=n-a></a>Gu Y, Sun X, Li B, <i> et al.</i>: Vaccination with a Paramyosin-Based Multi-Epitope Vaccine Elicits Significant Protective Immunity against <i>Trichinella spiralis</i> Infection in Mice. <i>Front Microbiol.</i> 2017; <b>8</b>: 1475. <a target=xrefwindow id=d5014e3652 href="http://www.ncbi.nlm.nih.gov/pubmed/28824599">PubMed Abstract </a> | <a target=xrefwindow id=d5014e3656 href="https://doi.org/10.3389/fmicb.2017.01475">Publisher Full Text </a> | <a target=xrefwindow id=d5014e3659 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5540943">Free Full Text </a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d5014e3668 class=n-a></a>Altschul SF, Gish W, Miller W, <i> et al.</i>: Basic local alignment search tool. <i>J Mol Biol.</i> 1990; <b>215</b>(3): 403–10. <a target=xrefwindow id=d5014e3679 href="http://www.ncbi.nlm.nih.gov/pubmed/2231712">PubMed Abstract </a> | <a target=xrefwindow id=d5014e3682 href="https://doi.org/ 10.1016/S0022-2836(05)80360-2">Publisher Full Text </a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d5014e3691 class=n-a></a>Wilkins MR, Gasteiger E, Bairoch A, <i> et al.</i>: Protein identification and analysis tools in the ExPASy server. <i>Methods Mol Biol.</i> 1999; <b>112</b>: 531–52. <a target=xrefwindow id=d5014e3702 href="http://www.ncbi.nlm.nih.gov/pubmed/10027275">PubMed Abstract </a> | <a target=xrefwindow id=d5014e3705 href="https://doi.org/10.1385/1-59259-584-7:531">Publisher Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d5014e3714 class=n-a></a>Magnan CN, Randall A, Baldi P: SOLpro: accurate sequence-based prediction of protein solubility. <i>Bioinformatics.</i> 2009; <b>25</b>(17): 2200–7. <a target=xrefwindow id=d5014e3722 href="http://www.ncbi.nlm.nih.gov/pubmed/19549632">PubMed Abstract </a> | <a target=xrefwindow id=d5014e3725 href="https://doi.org/10.1093/bioinformatics/btp386">Publisher Full Text </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d5014e3734 class=n-a></a>Buchan DWA, Minneci F, Nugent TCO, <i> et al.</i>: Scalable web services for the PSIPRED Protein Analysis Workbench. <i>Nucleic Acids Res.</i> 2013; <b>41</b>(W1): W349–57. <a target=xrefwindow id=d5014e3745 href="http://www.ncbi.nlm.nih.gov/pubmed/23748958">PubMed Abstract </a> | <a target=xrefwindow id=d5014e3748 href="https://doi.org/10.1093/nar/gkt381">Publisher Full Text </a> | <a target=xrefwindow id=d5014e3752 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3692098">Free Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d5014e3762 class=n-a></a>Yang J, Yan R, Roy A, <i> et al.</i>: The I-TASSER Suite: protein structure and function prediction. <i>Nat Methods.</i> 2015; <b>12</b>(1): 7–8. <a target=xrefwindow id=d5014e3773 href="http://www.ncbi.nlm.nih.gov/pubmed/25549265">PubMed Abstract </a> | <a target=xrefwindow id=d5014e3776 href="https://doi.org/10.1038/nmeth.3213">Publisher Full Text </a> | <a target=xrefwindow id=d5014e3780 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4428668">Free Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d5014e3789 class=n-a></a>Heo L, Park H, Seok C: GalaxyRefine: protein structure refinement driven by side-chain repacking. <i>Nucleic Acids Res.</i> 2013; <b>41</b>(Web Server issue): W384–8. <a target=xrefwindow id=d5014e3797 href="http://www.ncbi.nlm.nih.gov/pubmed/23737448">PubMed Abstract </a> | <a target=xrefwindow id=d5014e3800 href="https://doi.org/10.1093/nar/gkt458">Publisher Full Text </a> | <a target=xrefwindow id=d5014e3803 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3692086">Free Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d5014e3812 class=n-a></a>Wiederstein M, Sippl MJ: ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins. <i>Nucleic Acids Res.</i> 2007; <b>35</b>(Web Server issue): W407–10. <a target=xrefwindow id=d5014e3820 href="http://www.ncbi.nlm.nih.gov/pubmed/17517781">PubMed Abstract </a> | <a target=xrefwindow id=d5014e3823 href="https://doi.org/10.1093/nar/gkm290">Publisher Full Text </a> | <a target=xrefwindow id=d5014e3826 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1933241">Free Full Text </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d5014e3835 class=n-a></a>Eisenberg D, Lüthy R, Bowie JU: VERIFY3D: assessment of protein models with three-dimensional profiles. <i>Methods Enzymol.</i> 1997; <b>277</b>: 396–404. <a target=xrefwindow id=d5014e3843 href="http://www.ncbi.nlm.nih.gov/pubmed/9379925">PubMed Abstract </a> | <a target=xrefwindow id=d5014e3846 href="https://doi.org/10.1016/s0076-6879(97)77022-8">Publisher Full Text </a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d5014e3855 class=n-a></a>Lovell SC, Davis IW, Arendall WB, <i> et al.</i>: Structure validation by Cα geometry: ϕ,ψ and Cβ deviation. <i>Proteins Struct Funct Bioinforma.</i> 2003; <b>50</b>(3): 437–50. <a target=xrefwindow id=d5014e3866 href="https://doi.org/10.1002/prot.10286">Publisher Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d5014e3875 class=n-a></a>Laskowski RA, MacArthur MW, Moss DS, <i> et al.</i>: <i>PROCHECK</i>: a program to check the stereochemical quality of protein structures. <i>J Appl Crystallogr.</i> 1993; <b>26</b>(2): 283–91. <a target=xrefwindow id=d5014e3889 href="https://doi.org/10.1107/S0021889892009944">Publisher Full Text </a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d5014e3899 class=n-a></a>Hodder AN, Crewther PE, Matthew ML, <i> et al.</i>: The disulfide bond structure of <i>Plasmodium</i> apical membrane antigen-1. <i>J Biol Chem.</i> 1996; <b>271</b>(46): 29446–52. <a target=xrefwindow id=d5014e3913 href="http://www.ncbi.nlm.nih.gov/pubmed/8910611">PubMed Abstract </a> | <a target=xrefwindow id=d5014e3917 href="https://doi.org/10.1074/jbc.271.46.29446">Publisher Full Text </a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d5014e3926 class=n-a></a>Craig DB, Dombkowski AA: Disulfide by Design 2.0: a web-based tool for disulfide engineering in proteins. <i>BMC Bioinformatics.</i> 2013; <b>14</b>(1): 346. <a target=xrefwindow id=d5014e3934 href="http://www.ncbi.nlm.nih.gov/pubmed/24289175">PubMed Abstract </a> | <a target=xrefwindow id=d5014e3937 href="https://doi.org/10.1186/1471-2105-14-346">Publisher Full Text </a> | <a target=xrefwindow id=d5014e3940 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3898251">Free Full Text </a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d5014e3949 class=n-a></a>Grote A, Hiller K, Scheer M, <i> et al.</i>: JCat: a novel tool to adapt codon usage of a target gene to its potential expression host. <i>Nucleic Acids Res.</i> 2005; <b>33</b>(Web Server issue): W526–31. <a target=xrefwindow id=d5014e3960 href="http://www.ncbi.nlm.nih.gov/pubmed/15980527">PubMed Abstract </a> | <a target=xrefwindow id=d5014e3963 href="https://doi.org/10.1093/nar/gki376">Publisher Full Text </a> | <a target=xrefwindow id=d5014e3967 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1160137">Free Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a name=d5014e3976 class=n-a></a>Sharp PM, Li WH: The codon Adaptation Index--a measure of directional synonymous codon usage bias, and its potential applications. <i>Nucleic Acids Res.</i> 1987; <b>15</b>(3): 1281–95. <a target=xrefwindow id=d5014e3984 href="http://www.ncbi.nlm.nih.gov/pubmed/3547335">PubMed Abstract </a> | <a target=xrefwindow id=d5014e3987 href="https://doi.org/10.1093/nar/15.3.1281">Publisher Full Text </a> | <a target=xrefwindow id=d5014e3990 href="http://www.ncbi.nlm.nih.gov/pmc/articles/340524">Free Full Text </a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a name=d5014e3999 class=n-a></a>“SnapGene software (from Insightful Science; available at snapgene.com)”. </span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d5014e4008 class=n-a></a>Lengauer T, Rarey M: Computational methods for biomolecular docking. <i>Curr Opin Struct Biol.</i> 1996; <b>6</b>(3): 402–6. <a target=xrefwindow id=d5014e4016 href="http://www.ncbi.nlm.nih.gov/pubmed/8804827">PubMed Abstract </a> | <a target=xrefwindow id=d5014e4019 href="https://doi.org/10.1016/s0959-440x(96)80061-3">Publisher Full Text </a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d5014e4029 class=n-a></a>Hise AG, Traylor Z, Hall NB, <i> et al.</i>: Association of Symptoms and Severity of Rift Valley Fever with Genetic Polymorphisms in Human Innate Immune Pathways. <i>PLoS Negl Trop Dis.</i> 2015; <b>9</b>(3): e0003584. <a target=xrefwindow id=d5014e4040 href="http://www.ncbi.nlm.nih.gov/pubmed/25756647">PubMed Abstract </a> | <a target=xrefwindow id=d5014e4043 href="https://doi.org/10.1371/journal.pntd.0003584">Publisher Full Text </a> | <a target=xrefwindow id=d5014e4047 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4355584">Free Full Text </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d5014e4056 class=n-a></a>Berman HM, Battistuz T, Bhat TN, <i> et al.</i>: The Protein Data Bank. <i>Acta Crystallogr D Biol Crystallogr.</i> 2002; <b>58</b>(Pt 6 No 1): 899–907. <a target=xrefwindow id=d5014e4067 href="http://www.ncbi.nlm.nih.gov/pubmed/12037327">PubMed Abstract </a> | <a target=xrefwindow id=d5014e4070 href="https://doi.org/10.1107/s0907444902003451">Publisher Full Text </a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a name=d5014e4079 class=n-a></a>Kozakov D, Hall DR, Xia B, <i> et al.</i>: The ClusPro web server for protein–protein docking. <i>Nat Protoc.</i> 2017; <b>12</b>(2): 255–78. <a target=xrefwindow id=d5014e4090 href="http://www.ncbi.nlm.nih.gov/pubmed/28079879">PubMed Abstract </a> | <a target=xrefwindow id=d5014e4093 href="https://doi.org/10.1038/nprot.2016.169">Publisher Full Text </a> | <a target=xrefwindow id=d5014e4097 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5540229">Free Full Text </a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a name=d5014e4106 class=n-a></a>Aalten DMFV, Groot BLD, Findlay JBC, <i> et al.</i>: A comparison of techniques for calculating protein essential dynamics. <i>J Comput Chem.</i> 1997; <b>18</b>(2): 169–81. <a target="xrefwindow" id="d5014e4117" href="https://doi.org/10.1002/(SICI)1096-987X(19970130)18:2<169::AID-JCC3&gt;3.0.CO;2-T">Publisher Full Text </a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a name=d5014e4126 class=n-a></a>Wüthrich K, Wagner G, Richarz R, <i> et al.</i>: Correlations between internal mobility and stability of globular proteins. <i>Biophys J.</i> 1980; <b>32</b>(1): 549–60. <a target=xrefwindow id=d5014e4137 href="http://www.ncbi.nlm.nih.gov/pubmed/7248460">PubMed Abstract </a> | <a target=xrefwindow id=d5014e4140 href="https://doi.org/10.1016/S0006-3495(80)84989-7">Publisher Full Text </a> | <a target=xrefwindow id=d5014e4144 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1327351">Free Full Text </a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a name=d5014e4153 class=n-a></a>López-Blanco JR, Aliaga JI, Quintana-Ortí ES, <i> et al.</i>: iMODS: internal coordinates normal mode analysis server. <i>Nucleic Acids Res.</i> 2014; <b>42</b>(Web Server issue): W271–6. <a target=xrefwindow id=d5014e4164 href="http://www.ncbi.nlm.nih.gov/pubmed/24771341">PubMed Abstract </a> | <a target=xrefwindow id=d5014e4167 href="https://doi.org/10.1093/nar/gku339">Publisher Full Text </a> | <a target=xrefwindow id=d5014e4171 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4086069">Free Full Text </a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a name=d5014e4181 class=n-a></a>Lopéz-Blanco JR, Garzón JI, Chacón P: iMod: multipurpose normal mode analysis in internal coordinates. <i> Bioinformatics.</i> 2011; <b>27</b>(20): 2843–50. <a target=xrefwindow id=d5014e4189 href="http://www.ncbi.nlm.nih.gov/pubmed/21873636">PubMed Abstract </a> | <a target=xrefwindow id=d5014e4192 href="https://doi.org/10.1093/bioinformatics/btr497">Publisher Full Text </a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a name=d5014e4201 class=n-a></a>Rapin N, Lund O, Bernaschi M, <i> et al.</i>: Computational Immunology Meets Bioinformatics: The Use of Prediction Tools for Molecular Binding in the Simulation of the Immune System. <i>PLOS ONE.</i> 2010; <b>5</b>(4): e9862. <a target=xrefwindow id=d5014e4212 href="http://www.ncbi.nlm.nih.gov/pubmed/20419125">PubMed Abstract </a> | <a target=xrefwindow id=d5014e4215 href="https://doi.org/10.1371/journal.pone.0009862">Publisher Full Text </a> | <a target=xrefwindow id=d5014e4219 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2855701">Free Full Text </a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a name=d5014e4228 class=n-a></a>Castiglione F, Mantile F, De Berardinis P, <i> et al.</i>: How the Interval between Prime and Boost Injection Affects the Immune Response in a Computational Model of the Immune System. <i>Comput Math Methods Med.</i> Hindawi; 2012; <b>2012</b>: 842329. <a target=xrefwindow id=d5014e4239 href="http://www.ncbi.nlm.nih.gov/pubmed/22997539">PubMed Abstract </a> | <a target=xrefwindow id=d5014e4242 href="https://doi.org/10.1155/2012/842329">Publisher Full Text </a> | <a target=xrefwindow id=d5014e4246 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3446774">Free Full Text </a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a name=d5014e4255 class=n-a></a>Chen X, Jensen PE: The role of B lymphocytes as antigen-presenting cells. <i>Arch Immunol Ther Exp (Warsz).</i> 2008; <b>56</b>(2): 77–83. <a target=xrefwindow id=d5014e4263 href="http://www.ncbi.nlm.nih.gov/pubmed/18373241">PubMed Abstract </a> | <a target=xrefwindow id=d5014e4266 href="https://doi.org/10.1007/s00005-008-0014-5">Publisher Full Text </a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a name=d5014e4275 class=n-a></a>Kovacs JA, Chacón P, Abagyan R: Predictions of protein flexibility: First-order measures. <i>Proteins.</i> 2004; <b>56</b>(4): 661–8. <a target=xrefwindow id=d5014e4283 href="http://www.ncbi.nlm.nih.gov/pubmed/15281119">PubMed Abstract </a> | <a target=xrefwindow id=d5014e4286 href="https://doi.org/10.1002/prot.20151">Publisher Full Text </a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a name=d5014e4295 class=n-a></a>Zhang L: Multi-epitope vaccines: a promising strategy against tumors and viral infections. <i>Cell Mol Immunol.</i> 2018; <b>15</b>(2): 182–4. <a target=xrefwindow id=d5014e4303 href="http://www.ncbi.nlm.nih.gov/pubmed/28890542">PubMed Abstract </a> | <a target=xrefwindow id=d5014e4306 href="https://doi.org/10.1038/cmi.2017.92">Publisher Full Text </a> | <a target=xrefwindow id=d5014e4309 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5811687">Free Full Text </a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a name=d5014e4319 class=n-a></a>Shey RA, Ghogomu SM, Esoh KK, <i> et al.</i>: <i>In-silico</i> design of a multi-epitope vaccine candidate against onchocerciasis and related filarial diseases. <i>Sci Rep.</i> 2019; <b>9</b>(1): 4409. <a target=xrefwindow id=d5014e4333 href="http://www.ncbi.nlm.nih.gov/pubmed/30867498">PubMed Abstract </a> | <a target=xrefwindow id=d5014e4337 href="https://doi.org/10.1038/s41598-019-40833-x">Publisher Full Text </a> | <a target=xrefwindow id=d5014e4340 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6416346">Free Full Text </a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a name=d5014e4349 class=n-a></a>Seib KL, Zhao X, Rappuoli R: Developing vaccines in the era of genomics: a decade of reverse vaccinology. <i>Clin Microbiol Infect.</i> 2012; <b>18</b>(Suppl 5): 109–16. <a target=xrefwindow id=d5014e4357 href="http://www.ncbi.nlm.nih.gov/pubmed/22882709">PubMed Abstract </a> | <a target=xrefwindow id=d5014e4360 href="https://doi.org/10.1111/j.1469-0691.2012.03939.x">Publisher Full Text </a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a name=d5014e4369 class=n-a></a>María RAR, Arturo CVJ, Alicia JA, <i> et al.</i>: The Impact of Bioinformatics on Vaccine Design and Development. <i>Vaccines.</i> 2017. <a target=xrefwindow id=d5014e4377 href="https://doi.org/10.5772/INTECHOPEN.69273">Publisher Full Text </a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a name=d5014e4386 class=n-a></a>Dash R, Das R, Junaid M, <i> et al.</i>: In silico-based vaccine design against Ebola virus glycoprotein. <i>Adv Appl Bioinform Chem</i> . Dove Press; 2017; <b>10</b>: 11–28. <a target=xrefwindow id=d5014e4397 href="http://www.ncbi.nlm.nih.gov/pubmed/28356762">PubMed Abstract </a> | <a target=xrefwindow id=d5014e4400 href="https://doi.org/10.2147/AABC.S115859">Publisher Full Text </a> | <a target=xrefwindow id=d5014e4404 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5367765">Free Full Text </a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a name=d5014e4413 class=n-a></a>Ikram A, Zaheer T, Awan FM, <i> et al.</i>: Exploring NS3/4A, NS5A and NS5B proteins to design conserved subunit multi-epitope vaccine against HCV utilizing immunoinformatics approaches. <i>Sci Rep.</i> 2018; <b>8</b>(1): 16107. <a target=xrefwindow id=d5014e4424 href="http://www.ncbi.nlm.nih.gov/pubmed/30382118">PubMed Abstract </a> | <a target=xrefwindow id=d5014e4427 href="https://doi.org/10.1038/s41598-018-34254-5">Publisher Full Text </a> | <a target=xrefwindow id=d5014e4431 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6208421">Free Full Text </a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a name=d5014e4440 class=n-a></a>Adhikari UK, Tayebi M, Rahman MM: Immunoinformatics Approach for Epitope-Based Peptide Vaccine Design and Active Site Prediction against Polyprotein of Emerging Oropouche Virus. <i> J Immunol Res.</i> Hindawi. 2018; <b>2018</b>: 6718083. <a target=xrefwindow id=d5014e4448 href="http://www.ncbi.nlm.nih.gov/pubmed/30402510">PubMed Abstract </a> | <a target=xrefwindow id=d5014e4451 href="https://doi.org/10.1155/2018/6718083">Publisher Full Text </a> | <a target=xrefwindow id=d5014e4454 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6196980">Free Full Text </a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a name=d5014e4464 class=n-a></a>Ali M, Pandey RK, Khatoon N, <i> et al.</i>: Exploring dengue genome to construct a multi-epitope based subunit vaccine by utilizing immunoinformatics approach to battle against dengue infection. <i>Sci Rep.</i> 2017; <b>7</b>(1): 9232. <a target=xrefwindow id=d5014e4475 href="http://www.ncbi.nlm.nih.gov/pubmed/28835708">PubMed Abstract </a> | <a target=xrefwindow id=d5014e4478 href="https://doi.org/10.1038/s41598-017-09199-w">Publisher Full Text </a> | <a target=xrefwindow id=d5014e4482 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5569093">Free Full Text </a></span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a name=d5014e4491 class=n-a></a>Callaway E: The race for coronavirus vaccines: a graphical guide. <i>Nature.</i> 2020; <b>580</b>(7805): 576–7. <a target=xrefwindow id=d5014e4499 href="http://www.ncbi.nlm.nih.gov/pubmed/32346146">PubMed Abstract </a> | <a target=xrefwindow id=d5014e4502 href="https://doi.org/10.1038/d41586-020-01221-y">Publisher Full Text </a></span></li><li><a name=ref-80 class=n-a></a><span class=label>80. </span>&nbsp;<span class=citation><a name=d5014e4511 class=n-a></a>Cooper NR, Nemerow GR: The Role of Antibody and Complement in the Control of Viral Infections. <i>J Invest Dermatol.</i> 1984; <b>83</b>(1, Supplement): S121–7. <a target=xrefwindow id=d5014e4519 href="http://www.ncbi.nlm.nih.gov/pubmed/6376646">PubMed Abstract </a> | <a target=xrefwindow id=d5014e4522 href="https://doi.org/10.1111/1523-1747.ep12281847">Publisher Full Text </a></span></li><li><a name=ref-81 class=n-a></a><span class=label>81. </span>&nbsp;<span class=citation><a name=d5014e4531 class=n-a></a>Bacchetta R, Gregori S, Roncarolo MG: CD4<sup>+</sup> regulatory T cells: Mechanisms of induction and effector function. <i>Autoimmun Rev.</i> 2005; <b>4</b>(8): 491–6. <a target=xrefwindow id=d5014e4542 href="http://www.ncbi.nlm.nih.gov/pubmed/16214084">PubMed Abstract </a> | <a target=xrefwindow id=d5014e4545 href="https://doi.org/10.1016/j.autrev.2005.04.005">Publisher Full Text </a></span></li><li><a name=ref-82 class=n-a></a><span class=label>82. </span>&nbsp;<span class=citation><a name=d5014e4554 class=n-a></a>Garcia KC, Teyton L, Wilson IA: Structural Basis of T Cell Recognition. <i>Annu Rev Immunol.</i> 1999; <b>17</b>: 369–97. <a target=xrefwindow id=d5014e4562 href="http://www.ncbi.nlm.nih.gov/pubmed/10358763">PubMed Abstract </a> | <a target=xrefwindow id=d5014e4565 href="https://doi.org/10.1146/annurev.immunol.17.1.369">Publisher Full Text </a></span></li><li><a name=ref-83 class=n-a></a><span class=label>83. </span>&nbsp;<span class=citation><a name=d5014e4574 class=n-a></a>Dodd KA, McElroy AK, Jones MEB, <i> et al.</i>: Rift Valley fever virus clearance and protection from neurologic disease are dependent on CD4<sup>+</sup> T cell and virus-specific antibody responses. <i>J Virol.</i> 2013; <b>87</b>(11): 6161–71. <a target=xrefwindow id=d5014e4588 href="http://www.ncbi.nlm.nih.gov/pubmed/23536675">PubMed Abstract </a> | <a target=xrefwindow id=d5014e4592 href="https://doi.org/10.1128/JVI.00337-13">Publisher Full Text </a> | <a target=xrefwindow id=d5014e4595 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3648110">Free Full Text </a></span></li><li><a name=ref-84 class=n-a></a><span class=label>84. </span>&nbsp;<span class=citation><a name=d5014e4605 class=n-a></a>Adhikari UK, Rahman MM: Overlapping CD8+ and CD4+ T-cell epitopes identification for the progression of epitope-based peptide vaccine from nucleocapsid and glycoprotein of emerging Rift Valley fever virus using immunoinformatics approach. <i>Infect Genet Evol.</i> 2017; <b>56</b>: 75–91. <a target=xrefwindow id=d5014e4613 href="http://www.ncbi.nlm.nih.gov/pubmed/29107145">PubMed Abstract </a> | <a target=xrefwindow id=d5014e4616 href="https://doi.org/10.1016/j.meegid.2017.10.022">Publisher Full Text </a> | <a target=xrefwindow id=d5014e4619 href="http://www.ncbi.nlm.nih.gov/pmc/articles/7106247">Free Full Text </a></span></li><li><a name=ref-85 class=n-a></a><span class=label>85. </span>&nbsp;<span class=citation><a name=d5014e4628 class=n-a></a>Shamriz S, Ofoghi H, Moazami N: Effect of linker length and residues on the structure and stability of a fusion protein with malaria vaccine application. <i>Comput Biol Med.</i> 2016; <b>76</b>: 24–9. <a target=xrefwindow id=d5014e4636 href="http://www.ncbi.nlm.nih.gov/pubmed/27393958">PubMed Abstract </a> | <a target=xrefwindow id=d5014e4639 href="https://doi.org/10.1016/j.compbiomed.2016.06.015">Publisher Full Text </a></span></li><li><a name=ref-86 class=n-a></a><span class=label>86. </span>&nbsp;<span class=citation><a name=d5014e4648 class=n-a></a>Meza B, Ascencio F, Sierra-Beltrán AP, <i> et al.</i>: A novel design of a multi-antigenic, multistage and multi-epitope vaccine against Helicobacter pylori: An in silico approach. <i>Infect Genet Evol J Mol Epidemiol Evol Genet Infect Dis.</i> 2017; <b>49</b>: 309–17. <a target=xrefwindow id=d5014e4659 href="http://www.ncbi.nlm.nih.gov/pubmed/28185986">PubMed Abstract </a> | <a target=xrefwindow id=d5014e4662 href="https://doi.org/10.1016/j.meegid.2017.02.007">Publisher Full Text </a></span></li><li><a name=ref-87 class=n-a></a><span class=label>87. </span>&nbsp;<span class=citation><a name=d5014e4671 class=n-a></a>Lee S, Nguyen MT: Recent Advances of Vaccine Adjuvants for Infectious Diseases. <i>Immune Netw.</i> 2015; <b>15</b>(2): 51–7. <a target=xrefwindow id=d5014e4679 href="http://www.ncbi.nlm.nih.gov/pubmed/25922593">PubMed Abstract </a> | <a target=xrefwindow id=d5014e4682 href="https://doi.org/10.4110/in.2015.15.2.51">Publisher Full Text </a> | <a target=xrefwindow id=d5014e4685 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4411509">Free Full Text </a></span></li><li><a name=ref-88 class=n-a></a><span class=label>88. </span>&nbsp;<span class=citation><a name=d5014e4694 class=n-a></a>Bonam SR, Partidos CD, Halmuthur SKM, <i> et al.</i>: An Overview of Novel Adjuvants Designed for Improving Vaccine Efficacy. <i>Trends Pharmacol Sci.</i> 2017; <b>38</b>(9): 771–93. <a target=xrefwindow id=d5014e4705 href="http://www.ncbi.nlm.nih.gov/pubmed/28668223">PubMed Abstract </a> | <a target=xrefwindow id=d5014e4708 href="https://doi.org/10.1016/j.tips.2017.06.002">Publisher Full Text </a></span></li><li><a name=ref-89 class=n-a></a><span class=label>89. </span>&nbsp;<span class=citation><a name=d5014e4717 class=n-a></a>Gori A, Longhi R, Peri C, <i> et al.</i>: Peptides for immunological purposes: design, strategies and applications. <i>Amino Acids.</i> 2013; <b>45</b>(2): 257–68. <a target=xrefwindow id=d5014e4728 href="http://www.ncbi.nlm.nih.gov/pubmed/23744401">PubMed Abstract </a> | <a target=xrefwindow id=d5014e4731 href="https://doi.org/10.1007/s00726-013-1526-9">Publisher Full Text </a></span></li><li><a name=ref-90 class=n-a></a><span class=label>90. </span>&nbsp;<span class=citation><a name=d5014e4741 class=n-a></a>Chen R: Bacterial expression systems for recombinant protein production: <i>E. coli</i> and beyond. <i>Biotechnol Adv.</i> 2012; <b>30</b>(5): 1102–7. <a target=xrefwindow id=d5014e4752 href="http://www.ncbi.nlm.nih.gov/pubmed/21968145">PubMed Abstract </a> | <a target=xrefwindow id=d5014e4755 href="https://doi.org/10.1016/j.biotechadv.2011.09.013">Publisher Full Text </a></span></li><li><a name=ref-91 class=n-a></a><span class=label>91. </span>&nbsp;<span class=citation><a name=d5014e4764 class=n-a></a>Rosano GL, Ceccarelli EA: Recombinant protein expression in Escherichia coli: advances and challenges. <i>Front Microbiol.</i> 2014; <b>5</b>: 172. <a target=xrefwindow id=d5014e4772 href="http://www.ncbi.nlm.nih.gov/pubmed/24860555">PubMed Abstract </a> | <a target=xrefwindow id=d5014e4775 href="https://doi.org/10.3389/fmicb.2014.00172">Publisher Full Text </a> | <a target=xrefwindow id=d5014e4778 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4029002">Free Full Text </a></span></li><li><a name=ref-92 class=n-a></a><span class=label>92. </span>&nbsp;<span class=citation><a name=d5014e4787 class=n-a></a>Schmaljohn CS, Parker MD, Ennis WH, <i> et al.</i>: Baculovirus expression of the M genome segment of Rift Valley fever virus and examination of antigenic and immunogenic properties of the expressed proteins. <i>Virology.</i> 1989; <b>170</b>(1): 184–92. <a target=xrefwindow id=d5014e4798 href="http://www.ncbi.nlm.nih.gov/pubmed/2655274">PubMed Abstract </a> | <a target=xrefwindow id=d5014e4801 href="https://doi.org/10.1016/0042-6822(89)90365-6">Publisher Full Text </a></span></li></ul></div></div></div> </div> <div class=f1r-article-desk> <section class="o-box o-box--medium u-bg--2 u-mt--2"> <h4 class="u-mt--0 u-mb--2 t-h3 u-weight--md">Looking for the Open Peer Review Reports?</h4> <p class="u-mt--0 u-mb--0 t-h4">They can now be found at the top of the panel on the right, linked from the box entitled Open Peer Review. Choose the reviewer report you wish to read and click the 'read' link. You can also read all the peer review reports by <a target=_blank href="https://f1000research.com/articles/9-999/v1/pdf?article_uuid=53281b1e-d39a-4533-9629-211bb1c9d578">downloading the PDF</a>.</p> </section> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 18 Aug 2020</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/9-999/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/9-999/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Department of Virology, Bangabandhu Sheikh Mujib Medical University, Dhaka, 1000, Bangladesh<br/> <sup>2</sup> Department Biochemistry and Microbiology, North South University, Bashundhara, Dhaka, 1229, Bangladesh<br/> <sup>3</sup> Department of Biological Sciences, Faculty of Science, King Abdulaziz University, Jeddah, 21589, Saudi Arabia<br/> <sup>4</sup> Biological Solution Centre (BioSol Centre), Farmgate, Dhaka, 1215, Bangladesh<br/> <sup>5</sup> Department of Genetic Engineering and Biotechnology, Faculty of Biological Science and Technology, Jashore University of Science and Technology, Jashore, 7408, Bangladesh<br/> <sup>6</sup> Department of Genetic Engineering and Biotechnology, Faculty of Sciences and Engineering, East West University, Dhaka, 1212, Bangladesh<br/> <sup>7</sup> Department of Biotechnology and Genetic Engineering, Faculty of Biological Sciences, Islamic University, Kushtia, 7003, Bangladesh<br/> <p> <div class=margin-bottom> Maruf Ahmed Bhuiyan <br/> <span>Roles: </span> Data Curation, Formal Analysis, Investigation, Visualization, Writing – Original Draft Preparation </div> <div class=margin-bottom> Syeda Tasnim Quayum <br/> <span>Roles: </span> Formal Analysis, Investigation, Visualization, Writing – Original Draft Preparation </div> <div class=margin-bottom> Foysal Ahammad <br/> <span>Roles: </span> Resources, Writing – Review & Editing </div> <div class=margin-bottom> Rahat Alam <br/> <span>Roles: </span> Formal Analysis, Investigation, Visualization </div> <div class=margin-bottom> Abdus Samad <br/> <span>Roles: </span> Methodology, Resources, Supervision, Writing – Review & Editing </div> <div class=margin-bottom> Zulkar Nain <br/> <span>Roles: </span> Conceptualization, Methodology, Supervision, Validation, Writing – Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/9-999/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 18 Aug 2020, 9:999 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.24975.1">https://doi.org/10.12688/f1000research.24975.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2020 Bhuiyan MA <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=27552 data-id=24975 data-downloads="" data-views="" data-scholar="10.12688/f1000research.24975.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/9-999/v1/pdf?article_uuid=53281b1e-d39a-4533-9629-211bb1c9d578" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.24975.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Bhuiyan MA, Quayum ST, Ahammad F <em>et al.</em> Discovery of potential immune epitopes and peptide vaccine design - a prophylactic strategy against Rift Valley fever<i> </i>virus [version 1; peer review: awaiting peer review] <i>F1000Research</i> 2020, <b>9</b>:999 (<a href="https://doi.org/10.12688/f1000research.24975.1" target=_blank>https://doi.org/10.12688/f1000research.24975.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=24975 id=mobile-track-article-signin-24975 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/24975?target=/articles/9-999/v1"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=27552 /> <input name=articleId type=hidden value=24975 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status no-border-and-margin "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <div class=f1r-article-desk-inline><em>AWAITING PEER REVIEW</em></div> <div class="f1r-article-mobile-inline float-right"><em>AWAITING PEER REVIEW</em></div> <span class="circle-icon-small to-right" data-window=about-referee-status title=Help>?</span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 18 Aug 2020</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/9-999/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/9-999/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <div class="p-article__sidebar-highlight u-mb--2"> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="u-ib u-middle"><em>AWAITING PEER REVIEW</em></div> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/9-999/v1&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/9-999/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Discovery of potential immune epitopes and...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/9-999/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/9-999/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/9-999/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Bhuiyan MA et al.');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/9-999/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/9-999",
            templates : {
                twitter : "Discovery of potential immune epitopes and peptide vaccine design.... Bhuiyan MA et al., published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/9-999/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Discovery of potential immune epitopes and peptide vaccine design - a prophylactic strategy against Rift Valley fever virus", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Research Article", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Discovery of potential immune epitopes and peptide vaccine design - a prophylactic strategy against Rift Valley fever virus", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/24975/27552")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("articles", "article", "27552");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "69777": 0,
                           "69778": 0,
                           "69783": 0,
                           "69784": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "b2bd6927-a6fd-43ff-8d3e-0da74aa9cff3";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-999.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-999.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-999.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/9-999.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/9-999.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>